Visible node/edge number:
Node colors:
Node labels:

show label of nodes with degree >=

Node sizes:
Edge colors:
Edge widths factor:
Layout:

gravity >=

edgeLength =

GRN in network:

Notice: IE browser need to manually refresh (F5) this page after resetting the network.

This regulatory network was inferred from the input dataset. The miRNAs and mRNAs are presented as round and rectangle nodes respectively. The numerical value popped up upon mouse over the gene node is the log2 transformed fold-change of the gene expression between the two groups. All of the nodes are clickable, and the detailed information of the miRNAs/mRNAs and related cancer pathway will be displayed in another window. The edges between nodes are supported by both interactions (predicted or experimentally verified) and correlations learnt from cancer dataset. The numerical value popped up upon mouse over the edge is the correlation beat value (effect size) between the two nodes. The experimental evidences of the edges reported in previous cancer studies are highlighted by red/orange color. All of these information can be accessed by the "mouse-over" action. This network shows a full map of the miRNA-mRNA regulation of the input gene list(s), and the hub miRNAs (with the high network degree/betweenness centrality) would be the potential cancer drivers or tumor suppressors. The full result table can be accessed in the "Regulations" tab.

"miRNACancerMAP" is also a network visualization tool for users to draw their regulatory network by personal customization. Users can set the complexity of the network by limiting the number of nodes or edges. And the color of the nodes can be defined by different categories of the mRNAs and miRNAs, such as Gene-Ontology, pathway, and expression status. Users can also select to use network degree or network betweenness centrality to define the node size. And edges can be black or colored by the correlation. Purple edge means negative correlation (mostly found between miRNA and mRNA), and blue edge means positive correlation (found in PPI or miRNA-miRNA sponge effect). We can also add the protein-protein interactions (PPI) into the network. This result will show the cluster of genes regulated by some specific miRNAs. Additionally, miRNA-miRNA edges can be added by the "miRNA sponge" button, presenting some clusters of miRNAs that have the interactions via sponge effect.

miRNA-gene regulations

(Download full result)

Num microRNA           Gene miRNA log2FC miRNA pvalue Gene log2FC Gene pvalue Interaction Correlation beta Correlation P-value PMID Reported in cancer studies OLS miRNA effect size OLS covariates effect size
1 hsa-miR-107 WNT4 0.24 0.01708 -0.4 0.36379 PITA; miRNATAP -1.2 0 NA -1.09 type:1.62, stage:-0.04, histology:0.81, age:-0.02, gender:-0.77
2 hsa-miR-140-3p CAMK2B 0.55 0 -3.79 0 mirMAP -1.81 0 NA -1.03 type:-3.89, stage:-0.38, histology:-0.66, age:0, gender:-0.57
3 hsa-miR-186-5p CAMK2B -0.06 0.53529 -3.79 0 miRNAWalker2 validate; miRNATAP -0.97 5.0E-5 NA -0.92 type:-3.95, stage:-0.28, histology:-0.28, age:0, gender:-0.73
4 hsa-miR-330-5p NKD1 0.44 0.00533 0.62 0.18603 miRanda; miRNATAP -0.8 0 NA -0.88 type:-1.82, stage:0.28, histology:-1.18, age:0.01, gender:0.71
5 hsa-miR-29a-3p DKK1 -0.86 0 2.54 1.0E-5 miRNAWalker2 validate; miRTarBase -1.21 0 NA -0.83 type:2.02, stage:0.37, histology:0.35, age:-0.06, gender:-0.43
6 hsa-miR-107 FZD10 0.24 0.01708 1.19 0.00016 miRanda -0.69 1.0E-5 NA -0.8 type:-0.38, stage:0.1, histology:-0.79, age:-0.03, gender:-0.29
7 hsa-miR-532-5p WNT2 1.03 0 -3.92 0 miRNATAP -1.17 0 NA -0.78 type:-3.66, stage:0.1, histology:-0.17, age:-0.01, gender:0.11
8 hsa-miR-361-5p PRICKLE1 0.23 0.00962 -1.74 0 miRanda -0.91 0 NA -0.77 type:-0.42, stage:-0.03, histology:0.56, age:-0.01, gender:-0.26
9 hsa-miR-192-5p PRICKLE1 -0.5 0.00345 -1.74 0 miRNAWalker2 validate -0.65 0 NA -0.76 type:-2.05, stage:-0.24, histology:-0.14, age:-0.02, gender:-0.19
10 hsa-miR-374b-5p DKK2 -0.31 0.00301 0.71 0.03131 mirMAP -0.8 0 NA -0.74 type:0.15, stage:-0.08, histology:-0.21, age:0, gender:0.23
11 hsa-miR-374a-5p DKK2 0.02 0.86978 0.71 0.03131 mirMAP -0.77 0 NA -0.72 type:0.47, stage:-0.07, histology:-0.16, age:0, gender:0.27
12 hsa-miR-26b-3p AXIN2 -1.26 0 0.11 0.75298 MirTarget -0.59 3.0E-5 NA -0.71 type:-2.11, stage:0.37, histology:-0.37, age:0.02, gender:0.4
13 hsa-miR-192-3p SFRP1 -0.64 0.00027 -4.15 0 MirTarget -0.42 4.0E-5 NA -0.7 type:-5.27, stage:-0.22, histology:-0.53, age:-0.01, gender:-0.25
14 hsa-miR-455-5p SFRP2 -0.27 0.05813 0.47 0.28903 miRanda -0.8 0 NA -0.69 type:0.54, stage:0.69, histology:0.76, age:0, gender:-0.16
15 hsa-miR-532-5p SFRP4 1.03 0 2.13 0 MirTarget -0.27 0.03865 NA -0.69 type:3.18, stage:0, histology:0.18, age:-0.01, gender:0.1
16 hsa-miR-16-2-3p AXIN2 -0.03 0.80516 0.11 0.75298 mirMAP -0.64 0 NA -0.67 type:-0.55, stage:0.46, histology:0.04, age:0.01, gender:0.3
17 hsa-miR-590-5p DKK2 -0.1 0.31003 0.71 0.03131 miRanda -0.74 0 NA -0.66 type:0.97, stage:-0.03, histology:0.17, age:0, gender:0.14
18 hsa-miR-21-5p DAAM1 1.51 0 -0.82 3.0E-5 miRNAWalker2 validate -0.58 0 NA -0.64 type:-0.29, stage:0.13, histology:-0.1, age:0, gender:-0.01
19 hsa-miR-361-5p DKK2 0.23 0.00962 0.71 0.03131 miRanda -0.66 0.00028 NA -0.64 type:0.94, stage:-0.06, histology:0.02, age:-0.01, gender:0.07
20 hsa-miR-24-3p NKD1 -0.26 0.0069 0.62 0.18603 miRNAWalker2 validate -0.72 0.00289 NA -0.6 type:-1.49, stage:0.21, histology:-0.8, age:0.01, gender:0.71
21 hsa-miR-192-5p FZD7 -0.5 0.00345 -0.28 0.25656 miRNAWalker2 validate -0.59 0 NA -0.59 type:-0.73, stage:0.34, histology:0.23, age:-0.01, gender:-0.31
22 hsa-miR-192-3p PLCB4 -0.64 0.00027 0.84 0.00057 miRNATAP -0.56 0 NA -0.58 type:0.21, stage:-0.24, histology:-0.33, age:-0.02, gender:-0.34
23 hsa-miR-148a-3p PRKX -0.75 0 -0.24 0.24037 MirTarget -0.59 0 NA -0.58 type:0.55, stage:0.06, histology:0.67, age:-0.01, gender:-0.56
24 hsa-miR-15a-5p FZD10 0.35 0.00077 1.19 0.00016 miRNATAP -0.44 0.00326 NA -0.56 type:-0.07, stage:0.18, histology:-0.58, age:-0.03, gender:-0.27
25 hsa-miR-455-3p FZD10 -1.4 0 1.19 0.00016 PITA; miRNATAP -0.56 0 NA -0.56 type:-0.91, stage:0.19, histology:-0.5, age:-0.02, gender:-0.41
26 hsa-miR-532-5p PRICKLE1 1.03 0 -1.74 0 miRNATAP -0.72 0 NA -0.56 type:0.14, stage:-0.15, histology:0.55, age:-0.02, gender:-0.1
27 hsa-miR-16-5p AXIN2 -0.4 0.0001 0.11 0.75298 miRNAWalker2 validate; miRTarBase; MirTarget; miRNATAP -0.49 0.00421 NA -0.55 type:-0.86, stage:0.41, histology:-0.03, age:0.01, gender:0.46
28 hsa-miR-29a-5p NFATC2 -0.11 0.34962 -1.87 0 mirMAP; miRNATAP -0.58 6.0E-5 NA -0.55 type:-1.98, stage:0.06, histology:0.02, age:-0.01, gender:-0.54
29 hsa-miR-148a-3p PRICKLE2 -0.75 0 -1.36 0 MirTarget; miRNATAP -0.36 1.0E-5 NA -0.53 type:-1.96, stage:-0.29, histology:-0.36, age:-0.01, gender:-0.15
30 hsa-miR-23b-3p PRKCB -0.53 0 -1.62 0 mirMAP -0.29 0.00658 NA -0.52 type:-2.15, stage:-0.21, histology:-0.31, age:0, gender:0.14
31 hsa-miR-107 VANGL2 0.24 0.01708 -0.7 0.02922 miRanda -0.71 0 NA -0.52 type:2.19, stage:0.19, histology:1.53, age:-0.02, gender:-0.93
32 hsa-miR-548b-3p WNT2 -0.02 0.93082 -3.92 0 MirTarget -0.5 0 NA -0.52 type:-5.24, stage:0.2, histology:-0.45, age:0, gender:0.37
33 hsa-miR-193b-3p LEF1 -0.17 0.27202 2.66 0 miRNAWalker2 validate -0.53 0 NA -0.51 type:2.17, stage:0.06, histology:-0.17, age:0, gender:0.48
34 hsa-miR-26b-5p SFRP4 -1.11 0 2.13 0 miRNAWalker2 validate -0.77 0 NA -0.51 type:2.05, stage:0.07, histology:0.33, age:-0.01, gender:-0.08
35 hsa-miR-15b-5p CCND1 0.23 0.08248 -0.9 1.0E-5 miRNAWalker2 validate; miRTarBase; MirTarget; miRNATAP -0.54 0 NA -0.5 type:-0.61, stage:-0.07, histology:0.03, age:0.01, gender:0.17
36 hsa-miR-192-5p FZD1 -0.5 0.00345 -0.99 0 miRNAWalker2 validate -0.46 0 NA -0.5 type:-0.84, stage:0.07, histology:0.28, age:-0.01, gender:-0.56
37 hsa-miR-185-5p WNT5B 0.48 0 -1.14 0.00022 miRNAWalker2 validate -0.64 4.0E-5 NA -0.5 type:0.85, stage:-0.5, histology:0.41, age:0, gender:0.08
38 hsa-miR-326 NKD1 -1.88 0 0.62 0.18603 miRanda -0.46 3.0E-5 NA -0.49 type:-3.19, stage:0.26, histology:-1.23, age:0.02, gender:0.64
39 hsa-miR-374a-5p FZD3 0.02 0.86978 -0.43 0.07605 mirMAP -0.52 2.0E-5 NA -0.48 type:0.61, stage:-0.02, histology:0.5, age:0.01, gender:-0.01
40 hsa-miR-340-5p NKD1 -0 0.9685 0.62 0.18603 mirMAP -0.5 0.00902 NA -0.48 type:-1.78, stage:0.16, histology:-1.06, age:0.01, gender:0.71
41 hsa-miR-501-5p NKD1 1.15 0 0.62 0.18603 mirMAP -0.34 0.00492 NA -0.48 type:-1.39, stage:0.16, histology:-1.16, age:0.01, gender:0.71
42 hsa-miR-148a-5p PRICKLE2 -0.77 0 -1.36 0 mirMAP -0.35 0 NA -0.48 type:-1.65, stage:-0.27, histology:-0.2, age:-0.02, gender:-0.14
43 hsa-miR-505-3p WNT7B -1.2 0 -2.5 0 miRNATAP -0.34 0.00653 NA -0.48 type:4.02, stage:0.5, histology:4.02, age:-0.03, gender:-0.8
44 hsa-miR-326 AXIN2 -1.88 0 0.11 0.75298 miRanda -0.36 2.0E-5 NA -0.47 type:-2.48, stage:0.53, histology:-0.42, age:0.02, gender:0.42
45 hsa-miR-589-3p CAMK2B 1.17 0 -3.79 0 MirTarget -0.78 0 NA -0.47 type:-2.7, stage:-0.31, histology:0, age:0, gender:-0.8
46 hsa-miR-15b-5p AXIN2 0.23 0.08248 0.11 0.75298 miRTarBase; MirTarget; miRNATAP -0.45 0.00081 NA -0.46 type:-0.3, stage:0.42, histology:0.09, age:0.01, gender:0.49
47 hsa-miR-616-3p AXIN2 -0.7 2.0E-5 0.11 0.75298 MirTarget -0.42 8.0E-5 NA -0.46 type:-1.51, stage:0.43, histology:-0.29, age:0.02, gender:0.4
48 hsa-miR-28-5p CCND2 -0.43 0 0.36 0.03656 miRanda -0.48 0 NA -0.46 type:0.57, stage:0.02, histology:0.22, age:-0.01, gender:-0.07
49 hsa-miR-24-3p TCF7 -0.26 0.0069 0.32 0.14929 miRNATAP -0.56 0 NA -0.46 type:-0.08, stage:0.08, histology:-0.06, age:0, gender:0.57
50 hsa-miR-378a-5p VANGL2 -1.59 0 -0.7 0.02922 MirTarget -0.38 0 NA -0.46 type:0.75, stage:0.26, histology:1.3, age:-0.01, gender:-0.78
51 hsa-miR-34a-5p WNT7B 1.04 0 -2.5 0 mirMAP -0.87 0 NA -0.46 type:5.35, stage:0.49, histology:4.14, age:-0.03, gender:-0.78
52 hsa-miR-15b-3p CAMK2A 0.24 0.09977 -0.33 0.35691 mirMAP -0.44 0.00022 NA -0.45 type:1.14, stage:-0.11, histology:0.54, age:0, gender:-0.71
53 hsa-miR-361-5p FZD3 0.23 0.00962 -0.43 0.07605 miRanda; miRNATAP -0.46 0.0005 NA -0.45 type:0.93, stage:-0.01, histology:0.61, age:0.01, gender:-0.14
54 hsa-miR-26b-5p LEF1 -1.11 0 2.66 0 miRNATAP -0.88 0 24785257 miR26b is downregulated in several cancers and tumors and miR26b directly targets the lymphoid enhancer factor 1 Lef13'UTR and inhibits endogenous Lef1 expression; We report that miR26b expression is associated with human colon cancer through the regulation of LEF1 expression in colon cancer cells; Analyses of multiple colon cancer cell lines revealed an inverse correlation between miR26b and LEF1 expression; Normal human colon cells express low levels of LEF1 and high levels of miR26b; however human colon cancer cells have decreased miR26b expression and increased LEF1 expression; We demonstrate that miR26b expression is a potent inhibitor of colon cancer cell proliferation and significantly decreases LEF1 expression; Analyses of human colon cancer databases also demonstrated a link between miR26b and LEF1 expression -0.45 type:2.13, stage:0.09, histology:0.04, age:0, gender:0.24
55 hsa-miR-455-5p MMP7 -0.27 0.05813 -2.02 0.00038 miRanda -0.54 0.00528 NA -0.45 type:6.19, stage:0.51, histology:4.71, age:-0.02, gender:0.28
56 hsa-miR-331-3p TCF7 -0.28 0.03738 0.32 0.14929 MirTarget; miRNATAP -0.48 0 NA -0.45 type:-0.13, stage:0.12, histology:-0.06, age:0, gender:0.44
57 hsa-miR-28-5p WIF1 -0.43 0 0.56 0.11285 miRanda -0.5 0.00804 NA -0.45 type:2.39, stage:0.31, histology:1.28, age:-0.01, gender:0.14
58 hsa-miR-21-3p CAMK2A -0.48 0.003 -0.33 0.35691 MirTarget -0.43 5.0E-5 NA -0.44 type:1.09, stage:-0.09, histology:0.7, age:0, gender:-0.58
59 hsa-miR-335-5p DKK4 -1.61 0 1.46 0.00691 miRNAWalker2 validate -0.64 0 NA -0.44 type:-5.37, stage:-0.13, histology:-3.16, age:0, gender:0.84
60 hsa-let-7b-3p LEF1 -1.22 0 2.66 0 miRNATAP -0.67 0 NA -0.44 type:2.38, stage:0.08, histology:0.18, age:-0.01, gender:0.39
61 hsa-miR-548b-3p SFRP1 -0.02 0.93082 -4.15 0 mirMAP -0.43 0 NA -0.44 type:-4.2, stage:-0.07, histology:-0.08, age:-0.01, gender:0.09
62 hsa-miR-455-5p DKK2 -0.27 0.05813 0.71 0.03131 miRanda -0.45 6.0E-5 NA -0.43 type:0.95, stage:-0.15, histology:0.07, age:-0.01, gender:0.07
63 hsa-miR-16-1-3p SFRP1 0.39 0.00112 -4.15 0 MirTarget -0.72 0 NA -0.42 type:-3.3, stage:-0.1, histology:0.26, age:-0.01, gender:-0.13
64 hsa-miR-194-5p PRKCB -0.29 0.09961 -1.62 0 miRNATAP -0.31 0 NA -0.41 type:-2.53, stage:-0.31, histology:-0.67, age:0, gender:0.17
65 hsa-miR-33a-3p DKK2 -0.68 1.0E-5 0.71 0.03131 mirMAP -0.4 0.00011 NA -0.4 type:0.55, stage:-0.11, histology:0, age:-0.01, gender:0.17
66 hsa-miR-34a-5p PLCB1 1.04 0 1.21 0 miRNATAP -0.2 0.01117 NA -0.4 type:0.07, stage:0.2, histology:-0.62, age:0, gender:-0.19
67 hsa-miR-17-5p PRICKLE1 0.7 2.0E-5 -1.74 0 miRNAWalker2 validate -0.47 0 NA -0.4 type:0.01, stage:-0.12, histology:0.65, age:-0.02, gender:-0.25
68 hsa-miR-26b-3p PRKX -1.26 0 -0.24 0.24037 mirMAP -0.22 0.00569 NA -0.4 type:0.82, stage:0.16, histology:0.92, age:-0.02, gender:-0.71
69 hsa-miR-616-5p WNT2B 0.15 0.40284 0.92 9.0E-5 mirMAP -0.36 0 NA -0.4 type:-0.29, stage:0.02, histology:-0.67, age:-0.01, gender:-0.6
70 hsa-miR-7-1-3p CAMK2A -0.57 2.0E-5 -0.33 0.35691 MirTarget -0.36 0.00584 NA -0.39 type:1.03, stage:-0.1, histology:0.65, age:0, gender:-0.66
71 hsa-miR-16-5p CCND1 -0.4 0.0001 -0.9 1.0E-5 miRNAWalker2 validate; miRTarBase; MirTarget; miRNATAP -0.31 0.00178 23991964; 22922827; 18483394 At the molecular level our results further revealed that cyclin D1 expression was negatively regulated by miR-16;CCND1 has been found to be a target of miR-15a and miR-16-1 through analysis of complementary sequences between microRNAs and CCND1 mRNA; Moreover the transcription of CCND1 is suppressed by miR-15a and miR-16-1 via direct binding to the CCND1 3'-untranslated region 3'-UTR;Truncation in CCND1 mRNA alters miR 16 1 regulation in mantle cell lymphoma; Furthermore we demonstrated that this truncation alters miR-16-1 binding sites and through the use of reporter constructs we were able to show that miR-16-1 regulates CCND1 mRNA expression; This study introduces the role of miR-16-1 in the regulation of CCND1 in MCL -0.39 type:-1.28, stage:-0.09, histology:-0.19, age:0.01, gender:0.17
72 hsa-miR-193a-3p DAAM2 -0.12 0.30939 -0.83 6.0E-5 miRanda -0.34 0.0001 NA -0.39 type:-2.83, stage:-0.05, histology:-1.04, age:0, gender:0.1
73 hsa-miR-139-5p PLCB1 -2.11 0 1.21 0 miRanda -0.44 0 NA -0.39 type:-1.14, stage:0.04, histology:-0.72, age:-0.01, gender:-0.26
74 hsa-miR-378a-3p WNT10A -1.19 0 -0.7 0.01484 MirTarget; miRNATAP -0.31 1.0E-5 NA -0.39 type:2.73, stage:-0.07, histology:1.88, age:0.01, gender:0.15
75 hsa-miR-339-5p DAAM2 0.28 0.03557 -0.83 6.0E-5 miRanda -0.41 0 NA -0.38 type:-3.11, stage:-0.02, histology:-1.24, age:0, gender:0.09
76 hsa-miR-616-5p FZD2 0.15 0.40284 0.41 0.07557 MirTarget -0.34 0 NA -0.38 type:1.29, stage:0.25, histology:0.62, age:0, gender:-0.21
77 hsa-miR-30e-5p FZD3 -0.63 0 -0.43 0.07605 MirTarget -0.31 0.0078 NA -0.38 type:0.51, stage:-0.02, histology:0.57, age:0.01, gender:-0.14
78 hsa-miR-26a-5p LEF1 -0.96 0 2.66 0 miRNATAP -0.92 0 NA -0.38 type:2.56, stage:0.09, histology:0.19, age:-0.01, gender:0.25
79 hsa-miR-548j-5p SFRP1 0.25 0.17136 -4.15 0 MirTarget -0.45 1.0E-5 NA -0.38 type:-3.11, stage:-0.04, histology:0.47, age:-0.01, gender:-0.07
80 hsa-miR-92a-3p CCND1 0.21 0.13429 -0.9 1.0E-5 miRNAWalker2 validate -0.41 0 NA -0.37 type:-1.25, stage:-0.14, histology:-0.35, age:0.01, gender:0.14
81 hsa-miR-590-3p DKK2 -0.47 2.0E-5 0.71 0.03131 miRanda; mirMAP; miRNATAP -0.51 0.00043 NA -0.37 type:0.67, stage:-0.05, histology:0.06, age:-0.01, gender:0.14
82 hsa-miR-192-5p FZD9 -0.5 0.00345 -0.24 0.50534 miRNATAP -0.31 0.0031 NA -0.37 type:-0.25, stage:-0.08, histology:0.04, age:-0.05, gender:-0.86
83 hsa-miR-491-5p FZD9 -0.37 0.0154 -0.24 0.50534 miRanda -0.28 0.01668 NA -0.37 type:0.37, stage:0.04, histology:0.41, age:-0.05, gender:-0.93
84 hsa-miR-374b-5p PLCB4 -0.31 0.00301 0.84 0.00057 mirMAP -0.47 4.0E-5 NA -0.37 type:1.27, stage:-0.1, histology:0.2, age:-0.02, gender:-0.27
85 hsa-miR-148b-3p PRICKLE2 0.27 0.00185 -1.36 0 MirTarget; miRNATAP -0.46 0.00102 NA -0.37 type:-0.99, stage:-0.2, histology:-0.04, age:-0.02, gender:-0.28
86 hsa-miR-589-5p PRICKLE2 1.19 0 -1.36 0 MirTarget; miRNATAP -0.54 0 NA -0.37 type:-0.97, stage:-0.16, histology:-0.17, age:-0.02, gender:-0.22
87 hsa-miR-23b-3p PRKX -0.53 0 -0.24 0.24037 mirMAP -0.34 0.00031 NA -0.37 type:1.1, stage:0.15, histology:0.9, age:-0.02, gender:-0.65
88 hsa-miR-30c-1-3p FZD7 -1.39 0 -0.28 0.25656 MirTarget -0.24 0.00067 NA -0.36 type:0.06, stage:0.48, histology:0.84, age:-0.01, gender:-0.39
89 hsa-let-7a-3p LEF1 -0.57 0 2.66 0 miRNATAP -0.64 4.0E-5 NA -0.36 type:2.38, stage:0.12, histology:0.05, age:-0.01, gender:0.3
90 hsa-miR-25-3p CAMK2A 0.63 0 -0.33 0.35691 MirTarget -0.35 0.03714 NA -0.35 type:1.22, stage:-0.13, histology:0.49, age:0, gender:-0.67
91 hsa-miR-19b-1-5p CCND1 -0.28 0.07831 -0.9 1.0E-5 miRNAWalker2 validate; miRTarBase -0.31 0 NA -0.35 type:-1.42, stage:-0.17, histology:-0.37, age:0.01, gender:0.16
92 hsa-miR-7-1-3p CCND1 -0.57 2.0E-5 -0.9 1.0E-5 mirMAP -0.26 0.00057 NA -0.35 type:-1.42, stage:-0.04, histology:-0.2, age:0.01, gender:0.2
93 hsa-miR-374b-5p FZD3 -0.31 0.00301 -0.43 0.07605 mirMAP -0.31 0.00624 NA -0.35 type:0.57, stage:-0.03, histology:0.52, age:0.01, gender:-0.04
94 hsa-miR-374b-5p FZD8 -0.31 0.00301 -1.21 0 miRNAWalker2 validate -0.28 0.00823 NA -0.35 type:-2.91, stage:0.19, histology:-0.62, age:-0.02, gender:-0.46
95 hsa-miR-590-5p MAPK10 -0.1 0.31003 -1.09 3.0E-5 PITA; miRanda; miRNATAP -0.37 0.00397 NA -0.35 type:-0.08, stage:0, histology:0.53, age:-0.02, gender:-0.22
96 hsa-miR-590-5p SOX17 -0.1 0.31003 0.08 0.62256 miRanda -0.4 0 NA -0.35 type:-0.8, stage:-0.17, histology:-0.56, age:-0.01, gender:0.13
97 hsa-let-7g-3p AXIN2 -1.14 0 0.11 0.75298 MirTarget -0.33 0.01126 NA -0.34 type:-1.44, stage:0.41, histology:-0.23, age:0.01, gender:0.51
98 hsa-miR-195-3p AXIN2 -1.09 0 0.11 0.75298 mirMAP -0.31 0.00083 NA -0.34 type:-1.59, stage:0.35, histology:-0.37, age:0.01, gender:0.56
99 hsa-miR-106b-5p CCND1 0.65 0 -0.9 1.0E-5 miRNAWalker2 validate; miRTarBase; MirTarget; miRNATAP -0.43 0 NA -0.34 type:-0.8, stage:-0.06, histology:-0.11, age:0.01, gender:0.17
100 hsa-miR-425-5p CCND1 0.59 2.0E-5 -0.9 1.0E-5 miRNAWalker2 validate -0.39 0 NA -0.34 type:-1.19, stage:-0.09, histology:-0.33, age:0.01, gender:0.22
101 hsa-miR-361-5p PLCB4 0.23 0.00962 0.84 0.00057 miRanda -0.32 0.01855 NA -0.34 type:1.67, stage:-0.08, histology:0.31, age:-0.02, gender:-0.35
102 hsa-miR-374a-3p PRKX -0.21 0.06235 -0.24 0.24037 mirMAP -0.33 0.0002 NA -0.34 type:1, stage:0.2, histology:0.84, age:-0.02, gender:-0.58
103 hsa-miR-338-5p AXIN2 -0.22 0.25239 0.11 0.75298 miRNATAP -0.34 0.00017 NA -0.33 type:-0.63, stage:0.37, histology:-0.02, age:0.01, gender:0.42
104 hsa-miR-497-5p AXIN2 -1.41 0 0.11 0.75298 MirTarget; miRNATAP -0.29 0.00329 NA -0.33 type:-1.63, stage:0.35, histology:-0.35, age:0.01, gender:0.57
105 hsa-miR-616-5p CCND2 0.15 0.40284 0.36 0.03656 mirMAP -0.32 0 NA -0.33 type:0.2, stage:0.09, histology:-0.04, age:0, gender:-0.14
106 hsa-miR-92a-3p DAAM1 0.21 0.13429 -0.82 3.0E-5 miRNATAP -0.33 0 NA -0.33 type:-1.54, stage:0.05, histology:-0.36, age:0, gender:-0.22
107 hsa-miR-455-5p NFATC1 -0.27 0.05813 -0.75 4.0E-5 miRanda -0.31 0 NA -0.33 type:0.26, stage:-0.18, histology:0.39, age:-0.01, gender:-0.13
108 hsa-miR-589-5p VANGL2 1.19 0 -0.7 0.02922 mirMAP -0.4 0.00101 NA -0.33 type:2.56, stage:0.27, histology:1.65, age:-0.02, gender:-0.94
109 hsa-miR-664a-5p WNT7B -0.07 0.59768 -2.5 0 MirTarget -0.35 0.02085 NA -0.33 type:5.16, stage:0.44, histology:4.26, age:-0.04, gender:-0.97
110 hsa-miR-186-5p CCND1 -0.06 0.53529 -0.9 1.0E-5 mirMAP -0.32 0.00286 NA -0.32 type:-1.64, stage:-0.07, histology:-0.43, age:0.01, gender:0.25
111 hsa-miR-19b-3p CCND1 0.6 0.00017 -0.9 1.0E-5 miRNATAP -0.34 0 NA -0.32 type:-1.1, stage:-0.12, histology:-0.31, age:0.01, gender:0.15
112 hsa-miR-21-5p FZD4 1.51 0 -0.35 0.01097 mirMAP -0.32 0 NA -0.32 type:-1.57, stage:0.01, histology:-0.86, age:0.01, gender:0.1
113 hsa-miR-324-3p FZD4 0.26 0.05061 -0.35 0.01097 miRNATAP -0.33 0 NA -0.32 type:-2.29, stage:0, histology:-1.03, age:0.01, gender:0.02
114 hsa-miR-125b-5p PLCB1 -1.36 0 1.21 0 miRNATAP -0.43 0 NA -0.32 type:-0.76, stage:0.14, histology:-0.64, age:0, gender:-0.29
115 hsa-miR-374a-5p PLCB4 0.02 0.86978 0.84 0.00057 mirMAP -0.4 0.00081 NA -0.32 type:1.46, stage:-0.09, histology:0.24, age:-0.02, gender:-0.25
116 hsa-miR-590-3p PLCB4 -0.47 2.0E-5 0.84 0.00057 miRanda -0.41 0.00017 NA -0.32 type:1.41, stage:-0.06, histology:0.32, age:-0.02, gender:-0.32
117 hsa-miR-194-5p PRICKLE2 -0.29 0.09961 -1.36 0 miRNATAP -0.26 0.00014 NA -0.32 type:-1.82, stage:-0.3, histology:-0.44, age:-0.02, gender:-0.22
118 hsa-miR-589-5p PRKCB 1.19 0 -1.62 0 mirMAP -0.55 0 NA -0.32 type:-1.53, stage:-0.15, histology:-0.29, age:0, gender:0.17
119 hsa-miR-140-3p VANGL2 0.55 0 -0.7 0.02922 PITA; miRNATAP -0.75 5.0E-5 NA -0.32 type:2.18, stage:0.25, histology:1.55, age:-0.02, gender:-0.87
120 hsa-miR-378c WNT10A -1.54 0 -0.7 0.01484 MirTarget; miRNATAP -0.22 0.0013 NA -0.32 type:2.98, stage:-0.1, histology:1.99, age:0, gender:0.11
121 hsa-miR-340-5p CCND1 -0 0.9685 -0.9 1.0E-5 mirMAP -0.32 0.00013 NA -0.31 type:-1.39, stage:-0.1, histology:-0.33, age:0.01, gender:0.17
122 hsa-miR-616-5p CTBP2 0.15 0.40284 -0.39 0.02251 mirMAP -0.31 0 NA -0.31 type:1.05, stage:0.1, histology:0.78, age:-0.02, gender:-0.51
123 hsa-miR-106b-5p FZD4 0.65 0 -0.35 0.01097 miRNATAP -0.37 0 NA -0.31 type:-1.73, stage:0.03, histology:-0.78, age:0.01, gender:-0.02
124 hsa-let-7g-3p PLCB1 -1.14 0 1.21 0 miRNATAP -0.38 1.0E-5 NA -0.31 type:-0.3, stage:0.21, histology:-0.4, age:-0.01, gender:-0.37
125 hsa-miR-17-5p CCND1 0.7 2.0E-5 -0.9 1.0E-5 miRNAWalker2 validate; MirTarget; TargetScan; miRNATAP -0.34 0 26431674 Bioinformatics Prediction and In Vitro Analysis Revealed That miR 17 Targets Cyclin D1 mRNA in Triple Negative Breast Cancer Cells; In this study using bioinformatic analyses miR-17 was selected as it targets the 3'UTR of CCND1 gene with the highest score; After lentiviral transduction of miR-17 to the target cells gene expression analysis showed decreased expression of CCND1 gene -0.3 type:-1.14, stage:-0.13, histology:-0.35, age:0.01, gender:0.15
126 hsa-miR-18a-5p DAAM2 0.92 2.0E-5 -0.83 6.0E-5 miRNAWalker2 validate -0.32 0 NA -0.3 type:-2.59, stage:-0.05, histology:-1.08, age:0, gender:0.02
127 hsa-miR-23b-3p FZD3 -0.53 0 -0.43 0.07605 MirTarget -0.26 0.01785 NA -0.3 type:0.73, stage:-0.06, histology:0.6, age:0.01, gender:-0.09
128 hsa-miR-17-5p FZD4 0.7 2.0E-5 -0.35 0.01097 TargetScan -0.3 0 NA -0.3 type:-2.01, stage:-0.04, histology:-1, age:0.01, gender:-0.04
129 hsa-miR-221-3p MAPK10 1.12 0 -1.09 3.0E-5 miRNATAP -0.35 2.0E-5 NA -0.3 type:0.75, stage:-0.05, histology:0.72, age:-0.02, gender:-0.26
130 hsa-miR-181a-5p PRKCA 0.25 0.05519 0.66 0 mirMAP -0.25 0 NA -0.3 type:1.22, stage:0.1, histology:0.32, age:0, gender:-0.16
131 hsa-miR-30e-3p TCF7 -1.21 0 0.32 0.14929 mirMAP -0.35 6.0E-5 NA -0.3 type:-0.95, stage:0.06, histology:-0.4, age:0, gender:0.59
132 hsa-miR-27b-3p WNT3A -0.82 0 1.99 0 miRNATAP -0.55 0.00239 NA -0.3 type:4.87, stage:-0.34, histology:1.23, age:0.02, gender:-0.11
133 hsa-miR-335-5p WNT3A -1.61 0 1.99 0 mirMAP -0.47 2.0E-5 NA -0.3 type:5.17, stage:-0.33, histology:1.52, age:0.02, gender:-0.12
134 hsa-miR-195-5p AXIN2 -1.86 0 0.11 0.75298 MirTarget; miRNATAP -0.25 0.00506 NA -0.29 type:-1.59, stage:0.36, histology:-0.28, age:0.01, gender:0.55
135 hsa-miR-146b-3p CAMK2A -1.21 0 -0.33 0.35691 miRNATAP -0.26 0.00225 NA -0.29 type:0.37, stage:-0.19, histology:0.31, age:0, gender:-0.47
136 hsa-miR-20a-5p CCND1 0.85 0 -0.9 1.0E-5 miRNAWalker2 validate; miRTarBase; MirTarget; miRNATAP -0.33 0 NA -0.29 type:-1.11, stage:-0.13, histology:-0.37, age:0.01, gender:0.17
137 hsa-miR-455-5p LEF1 -0.27 0.05813 2.66 0 miRanda -0.35 0.00298 NA -0.29 type:2.57, stage:0.07, histology:0.02, age:-0.01, gender:0.28
138 hsa-miR-374a-3p PRICKLE2 -0.21 0.06235 -1.36 0 MirTarget; miRNATAP -0.27 0.0136 NA -0.29 type:-1.53, stage:-0.16, histology:-0.19, age:-0.02, gender:-0.17
139 hsa-miR-125a-5p RAC3 -0.91 0 0.67 0.00109 PITA -0.32 0 NA -0.29 type:-1.62, stage:0.13, histology:-0.89, age:0.01, gender:0.48
140 hsa-miR-33a-3p SFRP2 -0.68 1.0E-5 0.47 0.28903 miRNATAP -0.32 0.02258 NA -0.29 type:0.3, stage:0.74, histology:0.73, age:0.01, gender:-0.02
141 hsa-miR-618 CTBP2 0.14 0.51715 -0.39 0.02251 MirTarget; PITA -0.33 0 NA -0.28 type:1.22, stage:0.03, histology:0.8, age:-0.02, gender:-0.44
142 hsa-miR-107 FZD3 0.24 0.01708 -0.43 0.07605 MirTarget; miRanda -0.33 0.00541 NA -0.28 type:0.88, stage:-0.08, histology:0.55, age:0.01, gender:-0.07
143 hsa-miR-92a-3p FZD4 0.21 0.13429 -0.35 0.01097 mirMAP -0.27 0 NA -0.28 type:-2.16, stage:-0.05, histology:-0.99, age:0.01, gender:-0.04
144 hsa-miR-101-3p FZD6 -1.48 0 0.59 0.00374 miRNAWalker2 validate; MirTarget -0.31 1.0E-5 NA -0.28 type:0.86, stage:0.11, histology:0.44, age:0.01, gender:0.22
145 hsa-miR-7-1-3p LEF1 -0.57 2.0E-5 2.66 0 mirMAP -0.45 0.00035 NA -0.28 type:2.6, stage:0.15, histology:0.15, age:0, gender:0.32
146 hsa-miR-10b-3p CAMK2B 2.77 0 -3.79 0 mirMAP -0.45 0 NA -0.27 type:-4.47, stage:-0.33, histology:-1.02, age:0, gender:-0.77
147 hsa-miR-18a-5p CAMK2B 0.92 2.0E-5 -3.79 0 mirMAP -0.42 6.0E-5 NA -0.27 type:-2.7, stage:-0.37, histology:0.09, age:-0.01, gender:-0.9
148 hsa-miR-106a-5p CCND1 -0.46 0.00972 -0.9 1.0E-5 MirTarget; miRNATAP -0.26 0 NA -0.27 type:-1.52, stage:-0.06, histology:-0.31, age:0.01, gender:0.1
149 hsa-miR-193a-3p CCND1 -0.12 0.30939 -0.9 1.0E-5 MirTarget; PITA; miRanda -0.21 0.01806 NA -0.27 type:-1.16, stage:-0.11, histology:-0.21, age:0.01, gender:0.2
150 hsa-miR-616-5p CCND1 0.15 0.40284 -0.9 1.0E-5 mirMAP -0.26 1.0E-5 NA -0.27 type:-1.77, stage:-0.05, histology:-0.51, age:0.01, gender:0.18

Over-represented Gene Ontology Biological Process

NumGOOverlapSizeP ValueAdj. P Value
1 WNT SIGNALING PATHWAY 75 351 1.489e-102 6.927e-99
2 CANONICAL WNT SIGNALING PATHWAY 39 95 1.828e-63 4.253e-60
3 REGULATION OF WNT SIGNALING PATHWAY 49 310 3.499e-57 5.427e-54
4 NON CANONICAL WNT SIGNALING PATHWAY 35 140 7.759e-48 9.026e-45
5 NEGATIVE REGULATION OF WNT SIGNALING PATHWAY 36 197 7.82e-44 7.277e-41
6 REGULATION OF CANONICAL WNT SIGNALING PATHWAY 37 236 1.873e-42 1.453e-39
7 REGULATION OF ANATOMICAL STRUCTURE MORPHOGENESIS 52 1021 3.751e-35 2.493e-32
8 NEGATIVE REGULATION OF CANONICAL WNT SIGNALING PATHWAY 29 162 6.378e-35 3.71e-32
9 POSITIVE REGULATION OF RESPONSE TO STIMULUS 63 1929 2.584e-32 1.336e-29
10 BETA CATENIN DESTRUCTION COMPLEX DISASSEMBLY 16 22 8.322e-32 3.872e-29
11 REGULATION OF ORGAN MORPHOGENESIS 30 242 4.2e-31 1.777e-28
12 REGULATION OF MULTICELLULAR ORGANISMAL DEVELOPMENT 58 1672 1.146e-30 4.444e-28
13 POSITIVE REGULATION OF GENE EXPRESSION 57 1733 7.631e-29 2.731e-26
14 EPITHELIUM DEVELOPMENT 45 945 9.362e-29 3.112e-26
15 NEGATIVE REGULATION OF CELL COMMUNICATION 49 1192 1.279e-28 3.968e-26
16 POSITIVE REGULATION OF PROTEIN METABOLIC PROCESS 53 1492 3.905e-28 1.069e-25
17 REGULATION OF PROTEIN MODIFICATION PROCESS 56 1710 3.693e-28 1.069e-25
18 TISSUE MORPHOGENESIS 36 533 6.24e-28 1.613e-25
19 POSITIVE REGULATION OF CELL COMMUNICATION 53 1532 1.408e-27 3.449e-25
20 REGULATION OF EMBRYONIC DEVELOPMENT 22 114 2.456e-27 5.714e-25
21 TUBE MORPHOGENESIS 30 323 2.745e-27 6.083e-25
22 MORPHOGENESIS OF AN EPITHELIUM 32 400 4.601e-27 9.731e-25
23 NEGATIVE REGULATION OF RESPONSE TO STIMULUS 50 1360 4.99e-27 1.01e-24
24 WNT SIGNALING PATHWAY CALCIUM MODULATING PATHWAY 16 39 3.866e-26 7.495e-24
25 TISSUE DEVELOPMENT 51 1518 8.187e-26 1.524e-23
26 REGULATION OF PHOSPHORUS METABOLIC PROCESS 52 1618 1.767e-25 3.163e-23
27 ORGAN MORPHOGENESIS 40 841 2.429e-25 4.185e-23
28 REGULATION OF CELL DIFFERENTIATION 50 1492 3.393e-25 5.639e-23
29 POSITIVE REGULATION OF BIOSYNTHETIC PROCESS 54 1805 4.328e-25 6.945e-23
30 TUBE DEVELOPMENT 34 552 5.025e-25 7.794e-23
31 REGULATION OF ESTABLISHMENT OF PLANAR POLARITY 20 110 2.351e-24 3.529e-22
32 EMBRYO DEVELOPMENT ENDING IN BIRTH OR EGG HATCHING 33 554 8.143e-24 1.184e-21
33 EMBRYONIC MORPHOGENESIS 32 539 4.861e-23 6.853e-21
34 REGULATION OF CELLULAR PROTEIN LOCALIZATION 32 552 1.006e-22 1.377e-20
35 POSITIVE REGULATION OF PROTEIN MODIFICATION PROCESS 42 1135 1.876e-22 2.494e-20
36 EMBRYO DEVELOPMENT 38 894 2.72e-22 3.515e-20
37 POSITIVE REGULATION OF MOLECULAR FUNCTION 50 1791 1.166e-21 1.466e-19
38 PATTERN SPECIFICATION PROCESS 28 418 1.451e-21 1.777e-19
39 POSITIVE REGULATION OF PHOSPHATE METABOLIC PROCESS 39 1036 5.047e-21 5.87e-19
40 POSITIVE REGULATION OF PHOSPHORUS METABOLIC PROCESS 39 1036 5.047e-21 5.87e-19
41 REGULATION OF SEQUENCE SPECIFIC DNA BINDING TRANSCRIPTION FACTOR ACTIVITY 26 365 1.027e-20 1.166e-18
42 POSITIVE REGULATION OF CELL DIFFERENTIATION 35 823 1.756e-20 1.946e-18
43 POSITIVE REGULATION OF DEVELOPMENTAL PROCESS 40 1142 1.849e-20 2e-18
44 CARDIOVASCULAR SYSTEM DEVELOPMENT 34 788 4.431e-20 4.581e-18
45 CIRCULATORY SYSTEM DEVELOPMENT 34 788 4.431e-20 4.581e-18
46 REGIONALIZATION 24 311 5.735e-20 5.801e-18
47 POSITIVE REGULATION OF WNT SIGNALING PATHWAY 19 152 6.14e-20 6.079e-18
48 REGULATION OF BINDING 23 283 1.149e-19 1.114e-17
49 MORPHOGENESIS OF EMBRYONIC EPITHELIUM 18 134 1.632e-19 1.55e-17
50 REGULATION OF PROTEIN LOCALIZATION 36 950 1.94e-19 1.805e-17
51 ANATOMICAL STRUCTURE FORMATION INVOLVED IN MORPHOGENESIS 36 957 2.464e-19 2.248e-17
52 ANTERIOR POSTERIOR PATTERN SPECIFICATION 20 194 3.028e-19 2.709e-17
53 REGULATION OF TRANSCRIPTION FROM RNA POLYMERASE II PROMOTER 47 1784 3.446e-19 3.026e-17
54 INTRACELLULAR SIGNAL TRANSDUCTION 44 1572 7.486e-19 6.45e-17
55 NEURON DIFFERENTIATION 34 874 1.104e-18 9.339e-17
56 NEURAL TUBE DEVELOPMENT 18 149 1.16e-18 9.641e-17
57 REGULATION OF CELL CYCLE 35 949 1.637e-18 1.336e-16
58 GASTRULATION 18 155 2.394e-18 1.92e-16
59 TUBE FORMATION 17 129 2.46e-18 1.94e-16
60 NEUROGENESIS 41 1402 3.724e-18 2.888e-16
61 REGULATION OF INTRACELLULAR SIGNAL TRANSDUCTION 44 1656 5.416e-18 4.131e-16
62 REGULATION OF CELLULAR LOCALIZATION 39 1277 7.287e-18 5.469e-16
63 DORSAL VENTRAL AXIS SPECIFICATION 10 20 7.893e-18 5.829e-16
64 POSITIVE REGULATION OF CELLULAR COMPONENT ORGANIZATION 37 1152 1.273e-17 9.259e-16
65 NEURAL TUBE FORMATION 15 94 1.358e-17 9.718e-16
66 REGULATION OF ESTABLISHMENT OF PLANAR POLARITY INVOLVED IN NEURAL TUBE CLOSURE 9 14 1.566e-17 1.104e-15
67 REGULATION OF CELL PROLIFERATION 41 1496 3.729e-17 2.59e-15
68 CELL DEVELOPMENT 40 1426 4.637e-17 3.173e-15
69 REGULATION OF NUCLEOCYTOPLASMIC TRANSPORT 19 220 7.195e-17 4.852e-15
70 POSITIVE REGULATION OF TRANSCRIPTION FROM RNA POLYMERASE II PROMOTER 34 1004 7.549e-17 5.018e-15
71 REGULATION OF INTRACELLULAR PROTEIN TRANSPORT 23 381 8.556e-17 5.607e-15
72 REGULATION OF TRANSFERASE ACTIVITY 33 946 1.006e-16 6.501e-15
73 REGULATION OF RESPONSE TO STRESS 40 1468 1.259e-16 8.026e-15
74 REGULATION OF CELL DEATH 40 1472 1.382e-16 8.692e-15
75 POSITIVE REGULATION OF MULTICELLULAR ORGANISMAL PROCESS 39 1395 1.454e-16 9.021e-15
76 SENSORY ORGAN DEVELOPMENT 25 493 2.013e-16 1.232e-14
77 SEGMENTATION 14 89 2.12e-16 1.281e-14
78 CELL PROLIFERATION 28 672 3.81e-16 2.273e-14
79 NEGATIVE REGULATION OF DEVELOPMENTAL PROCESS 30 801 4.978e-16 2.932e-14
80 POSITIVE REGULATION OF CANONICAL WNT SIGNALING PATHWAY 15 119 5.335e-16 3.103e-14
81 HEART DEVELOPMENT 24 466 6.141e-16 3.528e-14
82 REGULATION OF CELLULAR RESPONSE TO STRESS 28 691 7.738e-16 4.391e-14
83 REGULATION OF CYTOPLASMIC TRANSPORT 24 481 1.247e-15 6.989e-14
84 CELLULAR RESPONSE TO ORGANIC SUBSTANCE 43 1848 1.857e-15 1.029e-13
85 CELL FATE COMMITMENT 18 227 2.254e-15 1.234e-13
86 SOMITOGENESIS 12 62 2.305e-15 1.247e-13
87 POSITIVE REGULATION OF CATALYTIC ACTIVITY 39 1518 2.418e-15 1.293e-13
88 POSITIVE REGULATION OF CELL DEATH 26 605 2.451e-15 1.296e-13
89 REGULATION OF PROTEIN TARGETING 20 307 2.481e-15 1.297e-13
90 REGULATION OF TRANSPORT 42 1804 4.41e-15 2.28e-13
91 REGULATION OF INTRACELLULAR TRANSPORT 26 621 4.545e-15 2.324e-13
92 PROTEIN PHOSPHORYLATION 31 944 5.453e-15 2.758e-13
93 SENSORY ORGAN MORPHOGENESIS 18 239 5.564e-15 2.784e-13
94 IMMUNE RESPONSE REGULATING CELL SURFACE RECEPTOR SIGNALING PATHWAY 20 323 6.546e-15 3.24e-13
95 FC EPSILON RECEPTOR SIGNALING PATHWAY 15 142 7.861e-15 3.85e-13
96 NEGATIVE REGULATION OF NITROGEN COMPOUND METABOLIC PROCESS 38 1517 1.394e-14 6.756e-13
97 REGULATION OF KINASE ACTIVITY 28 776 1.428e-14 6.848e-13
98 REGULATION OF CELL MORPHOGENESIS INVOLVED IN DIFFERENTIATION 20 337 1.465e-14 6.957e-13
99 MACROMOLECULAR COMPLEX DISASSEMBLY 16 182 1.769e-14 8.314e-13
100 REGULATION OF PROTEIN IMPORT 16 183 1.929e-14 8.975e-13
101 NEGATIVE REGULATION OF EMBRYONIC DEVELOPMENT 9 26 2.3e-14 1.06e-12
102 REGULATION OF CELL CYCLE PROCESS 24 558 3.308e-14 1.509e-12
103 REGULATION OF CATENIN IMPORT INTO NUCLEUS 9 27 3.432e-14 1.551e-12
104 REGULATION OF JNK CASCADE 15 159 4.284e-14 1.899e-12
105 SOMITE DEVELOPMENT 12 78 4.274e-14 1.899e-12
106 EMBRYONIC ORGAN DEVELOPMENT 21 406 4.537e-14 1.991e-12
107 NEGATIVE REGULATION OF GENE EXPRESSION 37 1493 4.833e-14 2.102e-12
108 DOPAMINERGIC NEURON DIFFERENTIATION 9 28 5.033e-14 2.168e-12
109 POSITIVE REGULATION OF CELL MORPHOGENESIS INVOLVED IN DIFFERENTIATION 15 162 5.66e-14 2.416e-12
110 REGULATION OF STRESS ACTIVATED PROTEIN KINASE SIGNALING CASCADE 16 197 6.147e-14 2.6e-12
111 REGULATION OF JUN KINASE ACTIVITY 12 81 6.855e-14 2.873e-12
112 BETA CATENIN TCF COMPLEX ASSEMBLY 10 43 7.291e-14 3.029e-12
113 REGULATION OF PROTEIN BINDING 15 168 9.713e-14 3.999e-12
114 CELL DEATH 30 1001 1.78e-13 7.265e-12
115 NEGATIVE REGULATION OF MOLECULAR FUNCTION 31 1079 1.975e-13 7.989e-12
116 AXIS SPECIFICATION 12 90 2.537e-13 1.018e-11
117 REGULATION OF HYDROLASE ACTIVITY 34 1327 2.693e-13 1.071e-11
118 REGULATION OF PROTEIN LOCALIZATION TO NUCLEUS 16 218 2.978e-13 1.174e-11
119 REGULATION OF ORGANELLE ORGANIZATION 32 1178 3.374e-13 1.319e-11
120 CELL MORPHOGENESIS INVOLVED IN DIFFERENTIATION 22 513 4.691e-13 1.819e-11
121 PROTEIN COMPLEX SUBUNIT ORGANIZATION 36 1527 5.237e-13 2.014e-11
122 POSITIVE REGULATION OF SEQUENCE SPECIFIC DNA BINDING TRANSCRIPTION FACTOR ACTIVITY 16 228 5.955e-13 2.271e-11
123 REGULATION OF CELL DEVELOPMENT 27 836 6.369e-13 2.409e-11
124 REGULATION OF PROTEIN SERINE THREONINE KINASE ACTIVITY 21 470 7.729e-13 2.9e-11
125 CONVERGENT EXTENSION 7 14 8.248e-13 3.07e-11
126 EMBRYONIC ORGAN MORPHOGENESIS 17 279 1.062e-12 3.921e-11
127 MORPHOGENESIS OF A BRANCHING STRUCTURE 14 167 1.614e-12 5.914e-11
128 FC RECEPTOR SIGNALING PATHWAY 15 206 1.932e-12 7.022e-11
129 NEGATIVE REGULATION OF TRANSCRIPTION FROM RNA POLYMERASE II PROMOTER 25 740 1.973e-12 7.116e-11
130 REGULATION OF CELL MORPHOGENESIS 22 552 2.011e-12 7.198e-11
131 PHOSPHATE CONTAINING COMPOUND METABOLIC PROCESS 40 1977 2.406e-12 8.546e-11
132 REGULATION OF PROTEIN CATABOLIC PROCESS 19 393 2.698e-12 9.509e-11
133 RHYTHMIC PROCESS 17 298 3.058e-12 1.07e-10
134 POSITIVE REGULATION OF INTRACELLULAR PROTEIN TRANSPORT 16 258 3.95e-12 1.372e-10
135 REGULATION OF STEM CELL DIFFERENTIATION 12 113 4.074e-12 1.404e-10
136 POSITIVE REGULATION OF JUN KINASE ACTIVITY 10 63 4.392e-12 1.497e-10
137 CELLULAR COMPONENT DISASSEMBLY 21 515 4.408e-12 1.497e-10
138 RESPONSE TO OXYGEN CONTAINING COMPOUND 33 1381 4.466e-12 1.506e-10
139 NEGATIVE REGULATION OF MULTICELLULAR ORGANISMAL PROCESS 28 983 4.522e-12 1.514e-10
140 HEAD DEVELOPMENT 24 709 5.608e-12 1.864e-10
141 PHOSPHORYLATION 31 1228 5.787e-12 1.91e-10
142 POSITIVE REGULATION OF CELLULAR PROTEIN LOCALIZATION 18 360 6.102e-12 1.985e-10
143 CELLULAR RESPONSE TO RETINOIC ACID 10 65 6.09e-12 1.985e-10
144 CELL CYCLE 32 1316 6.502e-12 2.101e-10
145 MIDBRAIN DEVELOPMENT 11 90 6.961e-12 2.234e-10
146 CELL CYCLE PROCESS 29 1081 7.513e-12 2.394e-10
147 DORSAL VENTRAL PATTERN FORMATION 11 91 7.879e-12 2.494e-10
148 REGULATION OF MAPK CASCADE 23 660 9.207e-12 2.894e-10
149 POSITIVE REGULATION OF NUCLEOCYTOPLASMIC TRANSPORT 12 121 9.267e-12 2.894e-10
150 MESENCHYME DEVELOPMENT 14 190 9.384e-12 2.911e-10
151 POSITIVE REGULATION OF INTRACELLULAR TRANSPORT 18 370 9.622e-12 2.965e-10
152 CELLULAR RESPONSE TO OXYGEN CONTAINING COMPOUND 25 799 1.045e-11 3.198e-10
153 DIGESTIVE TRACT MORPHOGENESIS 9 48 1.105e-11 3.359e-10
154 POSITIVE REGULATION OF CYTOPLASMIC TRANSPORT 16 282 1.515e-11 4.578e-10
155 POSITIVE REGULATION OF CELL CYCLE 17 332 1.701e-11 5.107e-10
156 POSITIVE REGULATION OF TRANSFERASE ACTIVITY 22 616 1.722e-11 5.136e-10
157 REGULATION OF NERVOUS SYSTEM DEVELOPMENT 24 750 1.814e-11 5.376e-10
158 NEGATIVE REGULATION OF BINDING 12 131 2.388e-11 6.989e-10
159 BRANCHING MORPHOGENESIS OF AN EPITHELIAL TUBE 12 131 2.388e-11 6.989e-10
160 COCHLEA MORPHOGENESIS 7 21 2.698e-11 7.847e-10
161 CELL ACTIVATION 21 568 2.768e-11 8e-10
162 POSITIVE REGULATION OF ORGANELLE ORGANIZATION 21 573 3.258e-11 9.357e-10
163 POSITIVE REGULATION OF STRESS ACTIVATED PROTEIN KINASE SIGNALING CASCADE 12 135 3.412e-11 9.738e-10
164 REGULATION OF IMMUNE SYSTEM PROCESS 32 1403 3.462e-11 9.823e-10
165 POSITIVE REGULATION OF ESTABLISHMENT OF PROTEIN LOCALIZATION 20 514 3.494e-11 9.852e-10
166 CELLULAR RESPONSE TO LIPID 19 457 3.683e-11 1.032e-09
167 HEART MORPHOGENESIS 14 212 4.103e-11 1.143e-09
168 NEGATIVE REGULATION OF PROTEIN BINDING 10 79 4.566e-11 1.265e-09
169 RESPONSE TO RETINOIC ACID 11 107 4.757e-11 1.31e-09
170 EPITHELIAL TO MESENCHYMAL TRANSITION 9 56 4.792e-11 1.311e-09
171 REPRODUCTIVE SYSTEM DEVELOPMENT 18 408 4.82e-11 1.311e-09
172 REGULATION OF MITOTIC CELL CYCLE 19 468 5.531e-11 1.496e-09
173 POSITIVE REGULATION OF PROTEIN CATABOLIC PROCESS 15 263 6.357e-11 1.71e-09
174 POSITIVE REGULATION OF CELL DEVELOPMENT 19 472 6.395e-11 1.71e-09
175 FORMATION OF PRIMARY GERM LAYER 11 110 6.447e-11 1.714e-09
176 REGULATION OF CATABOLIC PROCESS 23 731 7.113e-11 1.873e-09
177 RESPONSE TO GROWTH FACTOR 19 475 7.124e-11 1.873e-09
178 POSITIVE REGULATION OF INTRACELLULAR SIGNAL TRANSDUCTION 25 876 7.454e-11 1.948e-09
179 REGULATION OF OSTEOBLAST DIFFERENTIATION 11 112 7.855e-11 2.042e-09
180 PROTEASOMAL PROTEIN CATABOLIC PROCESS 15 271 9.69e-11 2.505e-09
181 POSITIVE REGULATION OF CELL PROLIFERATION 24 814 9.798e-11 2.519e-09
182 RESPONSE TO LIPID 25 888 9.935e-11 2.54e-09
183 NEGATIVE REGULATION OF CELL DIFFERENTIATION 21 609 1.004e-10 2.553e-09
184 MUSCLE STRUCTURE DEVELOPMENT 18 432 1.223e-10 3.093e-09
185 STEM CELL DIFFERENTIATION 13 190 1.362e-10 3.426e-09
186 MITOTIC CELL CYCLE 23 766 1.789e-10 4.475e-09
187 INNER EAR MORPHOGENESIS 10 92 2.14e-10 5.324e-09
188 MESODERM MORPHOGENESIS 9 66 2.226e-10 5.509e-09
189 GLAND DEVELOPMENT 17 395 2.55e-10 6.265e-09
190 REGULATION OF EPITHELIAL TO MESENCHYMAL TRANSITION 9 67 2.558e-10 6.265e-09
191 REGULATION OF PROTEOLYSIS 22 711 2.678e-10 6.523e-09
192 NEGATIVE REGULATION OF CELL PROLIFERATION 21 643 2.711e-10 6.569e-09
193 REGULATION OF IMMUNE RESPONSE 24 858 2.853e-10 6.879e-09
194 SIGNAL TRANSDUCTION BY PROTEIN PHOSPHORYLATION 17 404 3.605e-10 8.646e-09
195 CENTRAL NERVOUS SYSTEM DEVELOPMENT 24 872 3.953e-10 9.433e-09
196 POSITIVE REGULATION OF APOPTOTIC SIGNALING PATHWAY 12 171 5.407e-10 1.284e-08
197 POSITIVE REGULATION OF STEM CELL DIFFERENTIATION 8 50 6.167e-10 1.457e-08
198 POSITIVE REGULATION OF PROTEOLYSIS 16 363 6.335e-10 1.481e-08
199 REGULATION OF APOPTOTIC SIGNALING PATHWAY 16 363 6.335e-10 1.481e-08
200 STRESS ACTIVATED PROTEIN KINASE SIGNALING CASCADE 10 103 6.621e-10 1.54e-08
201 POSITIVE REGULATION OF KINASE ACTIVITY 18 482 7.114e-10 1.647e-08
202 REGULATION OF OSSIFICATION 12 178 8.581e-10 1.977e-08
203 REGULATION OF FAT CELL DIFFERENTIATION 10 106 8.806e-10 2.018e-08
204 IMMUNE SYSTEM PROCESS 36 1984 9.155e-10 2.088e-08
205 REGULATION OF MAP KINASE ACTIVITY 15 319 9.336e-10 2.119e-08
206 MAMMARY GLAND EPITHELIUM DEVELOPMENT 8 53 1.003e-09 2.265e-08
207 REGULATION OF CELLULAR COMPONENT BIOGENESIS 22 767 1.106e-09 2.487e-08
208 POSITIVE REGULATION OF EPITHELIAL TO MESENCHYMAL TRANSITION 7 34 1.17e-09 2.617e-08
209 RESPONSE TO TRANSFORMING GROWTH FACTOR BETA 11 144 1.19e-09 2.65e-08
210 REGULATION OF CELL ADHESION 20 629 1.206e-09 2.672e-08
211 REGULATION OF CELLULAR COMPONENT MOVEMENT 22 771 1.218e-09 2.687e-08
212 REGULATION OF GROWTH 20 633 1.345e-09 2.951e-08
213 EAR MORPHOGENESIS 10 112 1.518e-09 3.315e-08
214 PEPTIDYL SERINE MODIFICATION 11 148 1.594e-09 3.433e-08
215 DIGESTIVE SYSTEM DEVELOPMENT 11 148 1.594e-09 3.433e-08
216 OUTFLOW TRACT MORPHOGENESIS 8 56 1.583e-09 3.433e-08
217 POSITIVE REGULATION OF TRANSPORT 24 936 1.623e-09 3.48e-08
218 REGULATION OF CELL GROWTH 16 391 1.852e-09 3.954e-08
219 RESPONSE TO ABIOTIC STIMULUS 25 1024 1.906e-09 4.049e-08
220 NEGATIVE REGULATION OF CELL DEATH 23 872 2.194e-09 4.64e-08
221 MAMMARY GLAND DEVELOPMENT 10 117 2.332e-09 4.91e-08
222 POSITIVE REGULATION OF PROTEIN SERINE THREONINE KINASE ACTIVITY 14 289 2.399e-09 5.029e-08
223 SINGLE ORGANISM CELL ADHESION 17 459 2.5e-09 5.217e-08
224 MESODERM DEVELOPMENT 10 118 2.535e-09 5.266e-08
225 STEM CELL PROLIFERATION 8 60 2.795e-09 5.754e-08
226 REGULATION OF PHOSPHOPROTEIN PHOSPHATASE ACTIVITY 8 60 2.795e-09 5.754e-08
227 POSITIVE REGULATION OF CELLULAR COMPONENT BIOGENESIS 16 406 3.175e-09 6.508e-08
228 COCHLEA DEVELOPMENT 7 39 3.262e-09 6.657e-08
229 VASCULATURE DEVELOPMENT 17 469 3.453e-09 7.017e-08
230 POSITIVE REGULATION OF MAPK CASCADE 17 470 3.565e-09 7.212e-08
231 UROGENITAL SYSTEM DEVELOPMENT 14 299 3.713e-09 7.448e-08
232 DEVELOPMENTAL PROCESS INVOLVED IN REPRODUCTION 19 602 3.704e-09 7.448e-08
233 CELLULAR COMPONENT MORPHOGENESIS 23 900 3.996e-09 7.981e-08
234 CELL CYCLE PHASE TRANSITION 13 255 5.014e-09 9.97e-08
235 NEGATIVE REGULATION OF CELLULAR COMPONENT ORGANIZATION 20 684 5.038e-09 9.976e-08
236 REGULATION OF PROTEIN PHOSPHATASE TYPE 2A ACTIVITY 6 24 5.328e-09 1.051e-07
237 REGULATION OF PHOSPHATASE ACTIVITY 10 128 5.61e-09 1.101e-07
238 NEGATIVE REGULATION OF CELL GROWTH 11 170 6.886e-09 1.346e-07
239 CELLULAR RESPONSE TO ABIOTIC STIMULUS 13 263 7.264e-09 1.414e-07
240 RESPONSE TO DRUG 16 431 7.416e-09 1.438e-07
241 CELLULAR RESPONSE TO EXTERNAL STIMULUS 13 264 7.602e-09 1.468e-07
242 REGULATION OF CELL JUNCTION ASSEMBLY 8 68 7.755e-09 1.491e-07
243 REGULATION OF CELL SUBSTRATE ADHESION 11 173 8.269e-09 1.583e-07
244 MESENCHYMAL CELL DIFFERENTIATION 10 134 8.748e-09 1.668e-07
245 REGULATION OF CELL CYCLE PHASE TRANSITION 14 321 9.175e-09 1.742e-07
246 REGULATION OF CELL FATE SPECIFICATION 5 13 9.234e-09 1.747e-07
247 CELLULAR RESPONSE TO ACID CHEMICAL 11 175 9.324e-09 1.757e-07
248 CELLULAR RESPONSE TO STRESS 30 1565 9.961e-09 1.869e-07
249 PEPTIDYL THREONINE MODIFICATION 7 46 1.096e-08 2.048e-07
250 EYE DEVELOPMENT 14 326 1.116e-08 2.077e-07
251 DEVELOPMENTAL INDUCTION 6 27 1.155e-08 2.132e-07
252 AXIS ELONGATION 6 27 1.155e-08 2.132e-07
253 REGULATION OF CELLULAR PROTEIN CATABOLIC PROCESS 13 274 1.185e-08 2.179e-07
254 IMMUNE SYSTEM DEVELOPMENT 18 582 1.361e-08 2.494e-07
255 PROTEIN COMPLEX BIOGENESIS 25 1132 1.427e-08 2.593e-07
256 PROTEIN COMPLEX ASSEMBLY 25 1132 1.427e-08 2.593e-07
257 REGULATION OF CELLULAR RESPONSE TO GROWTH FACTOR STIMULUS 12 229 1.485e-08 2.689e-07
258 INNATE IMMUNE RESPONSE ACTIVATING CELL SURFACE RECEPTOR SIGNALING PATHWAY 9 106 1.613e-08 2.91e-07
259 POSITIVE REGULATION OF CATABOLIC PROCESS 15 395 1.677e-08 3.013e-07
260 REGULATION OF EPITHELIAL CELL PROLIFERATION 13 285 1.891e-08 3.384e-07
261 NEGATIVE REGULATION OF GROWTH 12 236 2.076e-08 3.7e-07
262 REGULATION OF MESODERM DEVELOPMENT 5 15 2.134e-08 3.79e-07
263 POSITIVE REGULATION OF HYDROLASE ACTIVITY 22 905 2.246e-08 3.973e-07
264 RESPONSE TO ENDOGENOUS STIMULUS 28 1450 2.988e-08 5.267e-07
265 PARAXIAL MESODERM DEVELOPMENT 5 16 3.089e-08 5.423e-07
266 RESPIRATORY SYSTEM DEVELOPMENT 11 197 3.183e-08 5.567e-07
267 POSITIVE REGULATION OF EPITHELIAL CELL PROLIFERATION 10 154 3.326e-08 5.796e-07
268 POSITIVE REGULATION OF CELL CYCLE PROCESS 12 247 3.435e-08 5.964e-07
269 REGULATION OF ORGAN FORMATION 6 32 3.449e-08 5.965e-07
270 FOREBRAIN DEVELOPMENT 14 357 3.49e-08 5.991e-07
271 KIDNEY MORPHOGENESIS 8 82 3.485e-08 5.991e-07
272 NEGATIVE REGULATION OF CELL MORPHOGENESIS INVOLVED IN DIFFERENTIATION 9 117 3.838e-08 6.566e-07
273 POSITIVE REGULATION OF EMBRYONIC DEVELOPMENT 6 33 4.194e-08 7.149e-07
274 REGULATION OF DEPHOSPHORYLATION 10 158 4.245e-08 7.208e-07
275 REGULATION OF CHROMATIN BINDING 5 17 4.355e-08 7.368e-07
276 PALATE DEVELOPMENT 8 85 4.635e-08 7.814e-07
277 LEUKOCYTE CELL CELL ADHESION 12 255 4.878e-08 8.194e-07
278 REPRODUCTION 26 1297 4.942e-08 8.271e-07
279 REGULATION OF MESENCHYMAL CELL PROLIFERATION 6 34 5.068e-08 8.422e-07
280 BRAIN MORPHOGENESIS 6 34 5.068e-08 8.422e-07
281 IN UTERO EMBRYONIC DEVELOPMENT 13 311 5.281e-08 8.727e-07
282 POSITIVE REGULATION OF MAP KINASE ACTIVITY 11 207 5.289e-08 8.727e-07
283 NEGATIVE REGULATION OF CELL CYCLE 15 433 5.626e-08 9.251e-07
284 EMBRYONIC PATTERN SPECIFICATION 7 58 5.8e-08 9.502e-07
285 POST ANAL TAIL MORPHOGENESIS 5 18 6e-08 9.762e-07
286 INOSITOL PHOSPHATE MEDIATED SIGNALING 5 18 6e-08 9.762e-07
287 REGULATION OF STEM CELL PROLIFERATION 8 88 6.098e-08 9.887e-07
288 KIDNEY EPITHELIUM DEVELOPMENT 9 125 6.825e-08 1.103e-06
289 RESPONSE TO ACID CHEMICAL 13 319 7.102e-08 1.143e-06
290 MESONEPHROS DEVELOPMENT 8 90 7.281e-08 1.168e-06
291 APPENDAGE DEVELOPMENT 10 169 8.023e-08 1.278e-06
292 LIMB DEVELOPMENT 10 169 8.023e-08 1.278e-06
293 REGULATION OF NON CANONICAL WNT SIGNALING PATHWAY 5 19 8.104e-08 1.287e-06
294 EMBRYONIC DIGIT MORPHOGENESIS 7 61 8.29e-08 1.312e-06
295 MESENCHYME MORPHOGENESIS 6 38 1.02e-07 1.609e-06
296 REGULATION OF MUSCLE ADAPTATION 7 63 1.041e-07 1.636e-06
297 DEVELOPMENTAL GROWTH 13 333 1.169e-07 1.831e-06
298 REGULATION OF MEIOTIC CELL CYCLE 6 40 1.404e-07 2.178e-06
299 POSITIVE REGULATION OF CELL MATRIX ADHESION 6 40 1.404e-07 2.178e-06
300 POSITIVE REGULATION OF ADHERENS JUNCTION ORGANIZATION 5 21 1.405e-07 2.178e-06
301 EYE MORPHOGENESIS 9 136 1.413e-07 2.185e-06
302 CELLULAR RESPONSE TO ORGANIC CYCLIC COMPOUND 15 465 1.419e-07 2.187e-06
303 LENS DEVELOPMENT IN CAMERA TYPE EYE 7 66 1.443e-07 2.217e-06
304 CELLULAR RESPONSE TO ENDOGENOUS STIMULUS 22 1008 1.488e-07 2.278e-06
305 REGULATION OF PROTEASOMAL PROTEIN CATABOLIC PROCESS 10 181 1.527e-07 2.33e-06
306 LYMPHOCYTE ACTIVATION 13 342 1.589e-07 2.417e-06
307 NEGATIVE REGULATION OF PHOSPHORUS METABOLIC PROCESS 16 541 1.718e-07 2.595e-06
308 NEGATIVE REGULATION OF PHOSPHATE METABOLIC PROCESS 16 541 1.718e-07 2.595e-06
309 CELL CELL SIGNALING 19 767 1.731e-07 2.607e-06
310 LOCOMOTION 23 1114 2.002e-07 3.005e-06
311 REGULATION OF MUSCLE TISSUE DEVELOPMENT 8 103 2.092e-07 3.1e-06
312 REGULATION OF CIRCADIAN RHYTHM 8 103 2.092e-07 3.1e-06
313 REGULATION OF MUSCLE ORGAN DEVELOPMENT 8 103 2.092e-07 3.1e-06
314 MUSCLE CELL DIFFERENTIATION 11 237 2.085e-07 3.1e-06
315 LEUKOCYTE ACTIVATION 14 414 2.158e-07 3.187e-06
316 MACROMOLECULAR COMPLEX ASSEMBLY 26 1398 2.168e-07 3.192e-06
317 POSITIVE REGULATION OF GROWTH 11 238 2.175e-07 3.192e-06
318 BIOLOGICAL ADHESION 22 1032 2.231e-07 3.264e-06
319 POSITIVE REGULATION OF PROTEIN IMPORT 8 104 2.255e-07 3.279e-06
320 DEVELOPMENTAL GROWTH INVOLVED IN MORPHOGENESIS 8 104 2.255e-07 3.279e-06
321 SCF DEPENDENT PROTEASOMAL UBIQUITIN DEPENDENT PROTEIN CATABOLIC PROCESS 5 23 2.3e-07 3.334e-06
322 POSITIVE REGULATION OF IMMUNE SYSTEM PROCESS 20 867 2.476e-07 3.578e-06
323 FAT CELL DIFFERENTIATION 8 106 2.614e-07 3.765e-06
324 POSITIVE REGULATION OF CELL JUNCTION ASSEMBLY 5 24 2.892e-07 4.153e-06
325 RESPONSE TO CYTOKINE 18 714 2.932e-07 4.198e-06
326 EAR DEVELOPMENT 10 195 3.053e-07 4.357e-06
327 EPITHELIAL CELL DIFFERENTIATION 15 495 3.16e-07 4.497e-06
328 BLOOD VESSEL MORPHOGENESIS 13 364 3.243e-07 4.601e-06
329 TRANSCRIPTION FROM RNA POLYMERASE II PROMOTER 18 724 3.593e-07 5.082e-06
330 NEGATIVE REGULATION OF MITOTIC CELL CYCLE 10 199 3.682e-07 5.192e-06
331 REGULATION OF CELLULAR RESPONSE TO HEAT 7 76 3.855e-07 5.419e-06
332 POSITIVE REGULATION OF NON CANONICAL WNT SIGNALING PATHWAY 4 11 4.071e-07 5.705e-06
333 REGULATION OF BMP SIGNALING PATHWAY 7 77 4.219e-07 5.895e-06
334 ANTERIOR POSTERIOR AXIS SPECIFICATION 6 48 4.316e-07 6.012e-06
335 REGULATION OF CELL FATE COMMITMENT 5 26 4.432e-07 6.156e-06
336 POSITIVE REGULATION OF CELL ADHESION 13 376 4.686e-07 6.489e-06
337 NEGATIVE REGULATION OF PROTEIN METABOLIC PROCESS 22 1087 5.391e-07 7.443e-06
338 POSITIVE REGULATION OF MESENCHYMAL CELL PROLIFERATION 5 27 5.413e-07 7.451e-06
339 REGULATION OF ADHERENS JUNCTION ORGANIZATION 6 50 5.534e-07 7.595e-06
340 REGULATION OF FIBROBLAST PROLIFERATION 7 81 5.98e-07 8.184e-06
341 RESPONSE TO ORGANIC CYCLIC COMPOUND 20 917 5.998e-07 8.184e-06
342 POSITIVE REGULATION OF FAT CELL DIFFERENTIATION 6 51 6.241e-07 8.491e-06
343 GASTRULATION WITH MOUTH FORMING SECOND 5 28 6.558e-07 8.896e-06
344 SEX DIFFERENTIATION 11 266 6.577e-07 8.896e-06
345 SKELETAL SYSTEM DEVELOPMENT 14 455 6.714e-07 9.055e-06
346 NEGATIVE REGULATION OF CELLULAR RESPONSE TO GROWTH FACTOR STIMULUS 8 121 7.232e-07 9.725e-06
347 CENTRAL NERVOUS SYSTEM NEURON DIFFERENTIATION 9 166 7.676e-07 1.026e-05
348 POSITIVE REGULATION OF OSSIFICATION 7 84 7.674e-07 1.026e-05
349 POSITIVE REGULATION OF MITOCHONDRION ORGANIZATION 9 167 8.073e-07 1.076e-05
350 CELL CELL ADHESION 16 608 8.139e-07 1.082e-05
351 RESPONSE TO METAL ION 12 333 8.601e-07 1.14e-05
352 REGULATION OF BICELLULAR TIGHT JUNCTION ASSEMBLY 4 13 8.737e-07 1.155e-05
353 REGULATION OF PROTEIN STABILITY 10 221 9.622e-07 1.268e-05
354 NEGATIVE REGULATION OF PROTEIN MODIFICATION PROCESS 16 616 9.662e-07 1.27e-05
355 WOUND HEALING 14 470 9.865e-07 1.289e-05
356 RESPONSE TO UV 8 126 9.844e-07 1.289e-05
357 REGULATION OF CHROMOSOME ORGANIZATION 11 278 1.015e-06 1.323e-05
358 REGULATION OF ESTABLISHMENT OF PROTEIN LOCALIZATION TO MITOCHONDRION 8 128 1.109e-06 1.442e-05
359 POSITIVE REGULATION OF PROTEIN LOCALIZATION TO NUCLEUS 8 129 1.177e-06 1.521e-05
360 REGULATION OF REPRODUCTIVE PROCESS 8 129 1.177e-06 1.521e-05
361 CALCIUM MEDIATED SIGNALING 7 90 1.228e-06 1.579e-05
362 REGULATION OF CELL MATRIX ADHESION 7 90 1.228e-06 1.579e-05
363 RESPONSE TO INORGANIC SUBSTANCE 14 479 1.234e-06 1.581e-05
364 GROWTH 13 410 1.237e-06 1.581e-05
365 PATTERNING OF BLOOD VESSELS 5 32 1.318e-06 1.68e-05
366 REGULATION OF DEVELOPMENTAL GROWTH 11 289 1.482e-06 1.879e-05
367 APOPTOTIC SIGNALING PATHWAY 11 289 1.482e-06 1.879e-05
368 EMBRYONIC AXIS SPECIFICATION 5 33 1.546e-06 1.955e-05
369 RESPONSE TO WOUNDING 15 563 1.587e-06 2.001e-05
370 ANGIOGENESIS 11 293 1.694e-06 2.131e-05
371 NEGATIVE REGULATION OF PHOSPHORYLATION 13 422 1.703e-06 2.136e-05
372 PROTEIN DESTABILIZATION 5 34 1.804e-06 2.256e-05
373 POSITIVE REGULATION OF STEM CELL PROLIFERATION 6 61 1.832e-06 2.285e-05
374 CELLULAR RESPONSE TO RADIATION 8 137 1.854e-06 2.306e-05
375 CELL CYCLE G2 M PHASE TRANSITION 8 138 1.958e-06 2.429e-05
376 RESPONSE TO ALCOHOL 12 362 2.056e-06 2.544e-05
377 REGULATION OF GASTRULATION 5 35 2.094e-06 2.585e-05
378 REGULATION OF CYTOSKELETON ORGANIZATION 14 502 2.137e-06 2.63e-05
379 APOPTOTIC PROCESS INVOLVED IN MORPHOGENESIS 4 16 2.193e-06 2.685e-05
380 CELL SURFACE RECEPTOR SIGNALING PATHWAY INVOLVED IN HEART DEVELOPMENT 4 16 2.193e-06 2.685e-05
381 REGULATION OF EPIDERMIS DEVELOPMENT 6 63 2.219e-06 2.71e-05
382 PROTEIN CATABOLIC PROCESS 15 579 2.24e-06 2.729e-05
383 POSITIVE REGULATION OF CELL SUBSTRATE ADHESION 7 99 2.34e-06 2.843e-05
384 PROTEIN DEPHOSPHORYLATION 9 190 2.359e-06 2.858e-05
385 POSITIVE REGULATION OF MITOCHONDRIAL OUTER MEMBRANE PERMEABILIZATION INVOLVED IN APOPTOTIC SIGNALING PATHWAY 5 36 2.42e-06 2.925e-05
386 REGULATION OF SMOOTH MUSCLE CELL PROLIFERATION 7 100 2.504e-06 3.018e-05
387 POSITIVE REGULATION OF INNATE IMMUNE RESPONSE 10 246 2.529e-06 3.041e-05
388 POSITIVE REGULATION OF CELLULAR PROTEIN CATABOLIC PROCESS 9 192 2.571e-06 3.075e-05
389 PROTEIN AUTOPHOSPHORYLATION 9 192 2.571e-06 3.075e-05
390 CAMERA TYPE EYE MORPHOGENESIS 7 101 2.677e-06 3.194e-05
391 CARDIAC CHAMBER DEVELOPMENT 8 144 2.694e-06 3.206e-05
392 CONNECTIVE TISSUE DEVELOPMENT 9 194 2.799e-06 3.323e-05
393 ESTABLISHMENT OF TISSUE POLARITY 4 17 2.854e-06 3.369e-05
394 REGULATION OF PRI MIRNA TRANSCRIPTION FROM RNA POLYMERASE II PROMOTER 4 17 2.854e-06 3.369e-05
395 NEGATIVE REGULATION OF TRANSMEMBRANE RECEPTOR PROTEIN SERINE THREONINE KINASE SIGNALING PATHWAY 7 102 2.86e-06 3.369e-05
396 CELLULAR RESPONSE TO UV 6 66 2.924e-06 3.427e-05
397 FOREBRAIN GENERATION OF NEURONS 6 66 2.924e-06 3.427e-05
398 RESPONSE TO OXYGEN LEVELS 11 311 3.013e-06 3.522e-05
399 PEPTIDYL AMINO ACID MODIFICATION 18 841 3.054e-06 3.561e-05
400 RESPONSE TO EXTERNAL STIMULUS 28 1821 3.106e-06 3.613e-05
401 CARDIAC CHAMBER MORPHOGENESIS 7 104 3.257e-06 3.78e-05
402 REGULATION OF PROTEASOMAL UBIQUITIN DEPENDENT PROTEIN CATABOLIC PROCESS 8 148 3.305e-06 3.807e-05
403 POSITIVE REGULATION OF CELL GROWTH 8 148 3.305e-06 3.807e-05
404 MALE SEX DIFFERENTIATION 8 148 3.305e-06 3.807e-05
405 REGULATION OF CELL MATURATION 4 18 3.653e-06 4.186e-05
406 PERICARDIUM DEVELOPMENT 4 18 3.653e-06 4.186e-05
407 REGULATION OF MUSCLE CELL DIFFERENTIATION 8 152 4.031e-06 4.608e-05
408 NEURAL PRECURSOR CELL PROLIFERATION 6 70 4.138e-06 4.707e-05
409 REGULATION OF MEMBRANE PERMEABILITY 6 70 4.138e-06 4.707e-05
410 NEGATIVE REGULATION OF TRANSPORT 13 458 4.175e-06 4.739e-05
411 REGULATION OF MYELOID LEUKOCYTE DIFFERENTIATION 7 108 4.191e-06 4.745e-05
412 ACTIVATION OF INNATE IMMUNE RESPONSE 9 204 4.224e-06 4.77e-05
413 NEURON PROJECTION GUIDANCE 9 205 4.395e-06 4.952e-05
414 NEGATIVE REGULATION OF NERVOUS SYSTEM DEVELOPMENT 10 262 4.431e-06 4.98e-05
415 NEGATIVE REGULATION OF NUCLEOCYTOPLASMIC TRANSPORT 6 71 4.497e-06 5.018e-05
416 SKIN EPIDERMIS DEVELOPMENT 6 71 4.497e-06 5.018e-05
417 ENDODERM DEVELOPMENT 6 71 4.497e-06 5.018e-05
418 POSITIVE REGULATION OF PROTEIN EXPORT FROM NUCLEUS 4 19 4.605e-06 5.126e-05
419 NEGATIVE REGULATION OF ESTABLISHMENT OF PROTEIN LOCALIZATION 9 209 5.144e-06 5.698e-05
420 LYMPHOCYTE DIFFERENTIATION 9 209 5.144e-06 5.698e-05
421 EMBRYONIC HEART TUBE DEVELOPMENT 6 73 5.293e-06 5.849e-05
422 NEGATIVE REGULATION OF BMP SIGNALING PATHWAY 5 42 5.305e-06 5.849e-05
423 NEURON PROJECTION DEVELOPMENT 14 545 5.511e-06 6.062e-05
424 SKIN DEVELOPMENT 9 211 5.557e-06 6.098e-05
425 TRACHEA DEVELOPMENT 4 20 5.73e-06 6.244e-05
426 POSITIVE REGULATION OF GLYCOPROTEIN METABOLIC PROCESS 4 20 5.73e-06 6.244e-05
427 BRANCHING INVOLVED IN MAMMARY GLAND DUCT MORPHOGENESIS 4 20 5.73e-06 6.244e-05
428 SECOND MESSENGER MEDIATED SIGNALING 8 160 5.892e-06 6.406e-05
429 REGULATION OF MUSCLE CELL APOPTOTIC PROCESS 5 43 5.974e-06 6.449e-05
430 MORPHOGENESIS OF AN EPITHELIAL SHEET 5 43 5.974e-06 6.449e-05
431 REGULATION OF MITOCHONDRIAL OUTER MEMBRANE PERMEABILIZATION INVOLVED IN APOPTOTIC SIGNALING PATHWAY 5 43 5.974e-06 6.449e-05
432 REGULATION OF CELL DIVISION 10 272 6.166e-06 6.641e-05
433 NEPHRON DEVELOPMENT 7 115 6.36e-06 6.819e-05
434 RESPONSE TO CALCIUM ION 7 115 6.36e-06 6.819e-05
435 REGULATION OF NEURON DIFFERENTIATION 14 554 6.641e-06 7.104e-05
436 LABYRINTHINE LAYER DEVELOPMENT 5 44 6.707e-06 7.142e-05
437 BRANCHING INVOLVED IN URETERIC BUD MORPHOGENESIS 5 44 6.707e-06 7.142e-05
438 APOPTOTIC PROCESS INVOLVED IN DEVELOPMENT 4 21 7.045e-06 7.484e-05
439 SPECIFICATION OF SYMMETRY 7 117 7.128e-06 7.555e-05
440 REGULATION OF MITOCHONDRION ORGANIZATION 9 218 7.236e-06 7.635e-05
441 REGULATION OF ACTIN FILAMENT BUNDLE ASSEMBLY 6 77 7.228e-06 7.635e-05
442 THYMOCYTE AGGREGATION 5 45 7.509e-06 7.887e-05
443 T CELL DIFFERENTIATION IN THYMUS 5 45 7.509e-06 7.887e-05
444 RENAL TUBULE DEVELOPMENT 6 78 7.792e-06 8.166e-05
445 RESPONSE TO RADIATION 12 413 7.899e-06 8.26e-05
446 REGULATION OF CYTOKINE PRODUCTION 14 563 7.972e-06 8.299e-05
447 POSITIVE REGULATION OF IMMUNE RESPONSE 14 563 7.972e-06 8.299e-05
448 SOMATIC STEM CELL DIVISION 4 22 8.57e-06 8.901e-05
449 REGULATION OF EPITHELIAL CELL DIFFERENTIATION 7 122 9.391e-06 9.732e-05
450 T CELL DIFFERENTIATION 7 123 9.908e-06 0.0001024
451 NEGATIVE REGULATION OF CATALYTIC ACTIVITY 17 829 1.035e-05 0.0001068
452 JNK CASCADE 6 82 1.042e-05 0.0001072
453 ACTIVATION OF IMMUNE RESPONSE 12 427 1.104e-05 0.0001134
454 HAIR CYCLE 6 83 1.117e-05 0.0001143
455 MOLTING CYCLE 6 83 1.117e-05 0.0001143
456 LEUKOCYTE DIFFERENTIATION 10 292 1.146e-05 0.0001169
457 CARDIAC SEPTUM MORPHOGENESIS 5 49 1.15e-05 0.0001171
458 OSTEOBLAST DIFFERENTIATION 7 126 1.16e-05 0.0001176
459 NEGATIVE REGULATION OF PROTEIN SERINE THREONINE KINASE ACTIVITY 7 126 1.16e-05 0.0001176
460 NEGATIVE REGULATION OF DEVELOPMENTAL GROWTH 6 84 1.197e-05 0.0001211
461 REGULATION OF VASCULATURE DEVELOPMENT 9 233 1.235e-05 0.0001246
462 CARDIAC SEPTUM DEVELOPMENT 6 85 1.282e-05 0.0001291
463 HEPATICOBILIARY SYSTEM DEVELOPMENT 7 128 1.286e-05 0.0001293
464 REGULATION OF GTPASE ACTIVITY 15 673 1.365e-05 0.0001369
465 POSITIVE REGULATION OF CYTOKINE PRODUCTION 11 370 1.554e-05 0.0001555
466 MAINTENANCE OF CELL NUMBER 7 132 1.572e-05 0.000157
467 POSITIVE REGULATION OF CELL PROJECTION ORGANIZATION 10 303 1.578e-05 0.0001572
468 RESPONSE TO NITROGEN COMPOUND 17 859 1.637e-05 0.0001628
469 REGULATION OF MORPHOGENESIS OF A BRANCHING STRUCTURE 5 53 1.697e-05 0.000168
470 MESONEPHRIC TUBULE MORPHOGENESIS 5 53 1.697e-05 0.000168
471 DEVELOPMENTAL PROGRAMMED CELL DEATH 4 26 1.719e-05 0.0001698
472 NEURON DEVELOPMENT 15 687 1.737e-05 0.0001713
473 EPITHELIAL CELL DEVELOPMENT 8 186 1.769e-05 0.000174
474 NEGATIVE REGULATION OF CELLULAR PROTEIN LOCALIZATION 7 135 1.819e-05 0.0001786
475 CELLULAR RESPONSE TO LIGHT STIMULUS 6 91 1.897e-05 0.0001858
476 CELLULAR RESPONSE TO EXTRACELLULAR STIMULUS 8 188 1.911e-05 0.0001868
477 RESPONSE TO LITHIUM ION 4 27 2.009e-05 0.0001959
478 MITOCHONDRIAL MEMBRANE ORGANIZATION 6 92 2.019e-05 0.0001966
479 REGULATION OF ACTIN FILAMENT BASED PROCESS 10 312 2.03e-05 0.0001972
480 REGULATION OF KIDNEY DEVELOPMENT 5 55 2.037e-05 0.0001975
481 PLACENTA DEVELOPMENT 7 138 2.098e-05 0.0002029
482 NEPHRON EPITHELIUM DEVELOPMENT 6 93 2.148e-05 0.0002069
483 REGULATION OF DNA BINDING 6 93 2.148e-05 0.0002069
484 NEGATIVE REGULATION OF KINASE ACTIVITY 9 250 2.159e-05 0.0002075
485 MITOTIC CELL CYCLE CHECKPOINT 7 139 2.198e-05 0.0002109
486 VENTRICULAR SEPTUM MORPHOGENESIS 4 28 2.332e-05 0.0002224
487 MORPHOGENESIS OF A POLARIZED EPITHELIUM 4 28 2.332e-05 0.0002224
488 MAMMARY GLAND DUCT MORPHOGENESIS 4 28 2.332e-05 0.0002224
489 PROTEIN LOCALIZATION 26 1805 2.396e-05 0.000228
490 NEGATIVE REGULATION OF INTRACELLULAR PROTEIN TRANSPORT 6 95 2.425e-05 0.0002298
491 TRANSFORMING GROWTH FACTOR BETA RECEPTOR SIGNALING PATHWAY 6 95 2.425e-05 0.0002298
492 MOVEMENT OF CELL OR SUBCELLULAR COMPONENT 21 1275 2.447e-05 0.0002314
493 REGULATION OF MUSCLE SYSTEM PROCESS 8 195 2.485e-05 0.0002346
494 TAXIS 12 464 2.511e-05 0.0002365
495 REGULATION OF PROTEIN INSERTION INTO MITOCHONDRIAL MEMBRANE INVOLVED IN APOPTOTIC SIGNALING PATHWAY 4 29 2.693e-05 0.0002506
496 POSITIVE REGULATION OF PROTEIN INSERTION INTO MITOCHONDRIAL MEMBRANE INVOLVED IN APOPTOTIC SIGNALING PATHWAY 4 29 2.693e-05 0.0002506
497 STEM CELL DIVISION 4 29 2.693e-05 0.0002506
498 REGULATION OF HEART MORPHOGENESIS 4 29 2.693e-05 0.0002506
499 RESPONSE TO HORMONE 17 893 2.684e-05 0.0002506
500 POSITIVE REGULATION OF PROTEIN COMPLEX ASSEMBLY 8 197 2.674e-05 0.0002506
501 SYNAPSE ORGANIZATION 7 145 2.886e-05 0.000268
502 NEGATIVE REGULATION OF CELL CYCLE PHASE TRANSITION 7 146 3.016e-05 0.0002796
503 CELL PROJECTION ORGANIZATION 17 902 3.047e-05 0.0002818
504 G PROTEIN COUPLED RECEPTOR SIGNALING PATHWAY 20 1193 3.059e-05 0.0002824
505 RESPONSE TO X RAY 4 30 3.093e-05 0.0002844
506 SKELETAL SYSTEM MORPHOGENESIS 8 201 3.087e-05 0.0002844
507 POSITIVE REGULATION OF OSTEOBLAST DIFFERENTIATION 5 60 3.123e-05 0.0002866
508 CARTILAGE DEVELOPMENT 7 147 3.151e-05 0.0002881
509 REGULATION OF CELL CYCLE G1 S PHASE TRANSITION 7 147 3.151e-05 0.0002881
510 NEGATIVE REGULATION OF LOCOMOTION 9 263 3.214e-05 0.0002932
511 REGULATION OF DNA TEMPLATED TRANSCRIPTION INITIATION 4 31 3.535e-05 0.0003218
512 CHROMOSOME ORGANIZATION 18 1009 3.588e-05 0.0003261
513 PROTEOLYSIS 20 1208 3.65e-05 0.000331
514 REGULATION OF SMOOTHENED SIGNALING PATHWAY 5 62 3.664e-05 0.0003311
515 EMBRYONIC HEART TUBE MORPHOGENESIS 5 62 3.664e-05 0.0003311
516 REGULATION OF TRANSMEMBRANE RECEPTOR PROTEIN SERINE THREONINE KINASE SIGNALING PATHWAY 8 207 3.806e-05 0.0003432
517 PALLIUM DEVELOPMENT 7 153 4.071e-05 0.0003664
518 RESPONSE TO MECHANICAL STIMULUS 8 210 4.215e-05 0.0003786
519 POSITIVE REGULATION BY HOST OF VIRAL TRANSCRIPTION 3 12 4.567e-05 0.0004055
520 REGULATION OF PROTEIN EXPORT FROM NUCLEUS 4 33 4.554e-05 0.0004055
521 TRACHEA MORPHOGENESIS 3 12 4.567e-05 0.0004055
522 POSITIVE REGULATION OF CATENIN IMPORT INTO NUCLEUS 3 12 4.567e-05 0.0004055
523 MAMMARY GLAND EPITHELIAL CELL PROLIFERATION 3 12 4.567e-05 0.0004055
524 REGULATION OF WNT SIGNALING PATHWAY PLANAR CELL POLARITY PATHWAY 3 12 4.567e-05 0.0004055
525 POSITIVE REGULATION OF DEVELOPMENTAL GROWTH 7 156 4.607e-05 0.0004075
526 CELLULAR RESPONSE TO INORGANIC SUBSTANCE 7 156 4.607e-05 0.0004075
527 REGULATION OF CYSTEINE TYPE ENDOPEPTIDASE ACTIVITY 8 213 4.66e-05 0.0004114
528 CHROMATIN ORGANIZATION 14 663 4.857e-05 0.000428
529 POSITIVE REGULATION OF LOCOMOTION 11 420 4.953e-05 0.0004357
530 SOMATIC STEM CELL POPULATION MAINTENANCE 5 66 4.964e-05 0.0004358
531 REGULATION OF PROTEIN DEACETYLATION 4 34 5.137e-05 0.0004498
532 DEVELOPMENT OF PRIMARY SEXUAL CHARACTERISTICS 8 216 5.143e-05 0.0004498
533 RESPONSE TO LIGHT STIMULUS 9 280 5.228e-05 0.0004564
534 REGULATION OF DNA TEMPLATED TRANSCRIPTION IN RESPONSE TO STRESS 5 67 5.339e-05 0.0004643
535 REGULATION OF SISTER CHROMATID SEGREGATION 5 67 5.339e-05 0.0004643
536 NEGATIVE REGULATION OF TRANSFERASE ACTIVITY 10 351 5.5e-05 0.0004775
537 BONE REMODELING 4 35 5.773e-05 0.0005002
538 CELL CYCLE G1 S PHASE TRANSITION 6 111 5.841e-05 0.0005042
539 G1 S TRANSITION OF MITOTIC CELL CYCLE 6 111 5.841e-05 0.0005042
540 HEMATOPOIETIC STEM CELL PROLIFERATION 3 13 5.91e-05 0.0005083
541 REGULATION OF SKELETAL MUSCLE ADAPTATION 3 13 5.91e-05 0.0005083
542 REGULATION OF NUCLEAR DIVISION 7 163 6.086e-05 0.0005215
543 CELLULAR RESPONSE TO BIOTIC STIMULUS 7 163 6.086e-05 0.0005215
544 DEPHOSPHORYLATION 9 286 6.156e-05 0.0005256
545 SYNAPSE ASSEMBLY 5 69 6.153e-05 0.0005256
546 REGULATION OF INNATE IMMUNE RESPONSE 10 357 6.336e-05 0.0005399
547 HEAD MORPHOGENESIS 4 36 6.464e-05 0.0005499
548 MUSCLE ORGAN MORPHOGENESIS 5 70 6.594e-05 0.0005599
549 CELLULAR RESPONSE TO ALCOHOL 6 115 7.117e-05 0.0006032
550 REGULATION OF MUSCLE HYPERTROPHY 4 37 7.214e-05 0.0006103
551 RESPONSE TO CARBOHYDRATE 7 168 7.364e-05 0.0006219
552 POSITIVE REGULATION OF DEFENSE RESPONSE 10 364 7.444e-05 0.0006275
553 POSITIVE REGULATION OF MEIOTIC CELL CYCLE 3 14 7.489e-05 0.0006279
554 CELL MIGRATION INVOLVED IN GASTRULATION 3 14 7.489e-05 0.0006279
555 REGULATION OF MONOCYTE DIFFERENTIATION 3 14 7.489e-05 0.0006279
556 TELENCEPHALON DEVELOPMENT 8 228 7.516e-05 0.000629
557 RESPONSE TO EXTRACELLULAR STIMULUS 11 441 7.665e-05 0.0006403
558 NEGATIVE REGULATION OF CYTOPLASMIC TRANSPORT 6 117 7.834e-05 0.0006533
559 POSITIVE REGULATION OF PROTEIN BINDING 5 73 8.067e-05 0.0006702
560 PANCREAS DEVELOPMENT 5 73 8.067e-05 0.0006702
561 CELL MORPHOGENESIS INVOLVED IN NEURON DIFFERENTIATION 10 368 8.149e-05 0.0006759
562 REGULATION OF PEPTIDYL SERINE PHOSPHORYLATION 6 118 8.213e-05 0.00068
563 NEURAL CREST CELL DIFFERENTIATION 5 75 9.18e-05 0.0007587
564 NEGATIVE REGULATION OF DENDRITE MORPHOGENESIS 3 15 9.32e-05 0.0007689
565 REGULATION OF PROTEIN COMPLEX ASSEMBLY 10 375 9.519e-05 0.0007839
566 NEGATIVE REGULATION OF CELL DEVELOPMENT 9 303 9.571e-05 0.0007868
567 MAMMARY GLAND MORPHOGENESIS 4 40 9.844e-05 0.0008064
568 NEGATIVE REGULATION OF OSTEOBLAST DIFFERENTIATION 4 40 9.844e-05 0.0008064
569 MITOCHONDRIAL TRANSPORT 7 177 0.0001021 0.0008352
570 CHROMATIN MODIFICATION 12 539 0.0001058 0.0008633
571 NEGATIVE REGULATION OF FAT CELL DIFFERENTIATION 4 41 0.0001086 0.0008847
572 CELL DIVISION 11 460 0.0001113 0.0009054
573 ORGAN INDUCTION 3 16 0.0001142 0.0009274
574 EPITHELIAL CELL MORPHOGENESIS 4 42 0.0001194 0.0009665
575 GENITALIA DEVELOPMENT 4 42 0.0001194 0.0009665
576 POSITIVE REGULATION OF BINDING 6 127 0.0001233 0.0009959
577 CELLULAR RESPONSE TO MECHANICAL STIMULUS 5 80 0.0001248 0.001007
578 REGULATION OF MYELOID CELL DIFFERENTIATION 7 183 0.0001257 0.001012
579 MUSCLE CELL DEVELOPMENT 6 128 0.0001287 0.001034
580 NEGATIVE REGULATION OF STEM CELL DIFFERENTIATION 4 43 0.0001311 0.00105
581 REGULATION OF GLYCOPROTEIN METABOLIC PROCESS 4 43 0.0001311 0.00105
582 REGULATION OF NFAT PROTEIN IMPORT INTO NUCLEUS 3 17 0.0001381 0.001102
583 CELLULAR RESPONSE TO LITHIUM ION 3 17 0.0001381 0.001102
584 BODY MORPHOGENESIS 4 44 0.0001435 0.001143
585 REGULATION OF CELL PROJECTION ORGANIZATION 12 558 0.0001462 0.001159
586 PROTEIN STABILIZATION 6 131 0.0001462 0.001159
587 OSSIFICATION 8 251 0.0001462 0.001159
588 MACROMOLECULE CATABOLIC PROCESS 16 926 0.0001466 0.00116
589 EMBRYONIC PLACENTA DEVELOPMENT 5 83 0.0001486 0.001172
590 NIK NF KAPPAB SIGNALING 5 83 0.0001486 0.001172
591 CELLULAR MACROMOLECULE LOCALIZATION 19 1234 0.0001521 0.001198
592 EPIDERMIS DEVELOPMENT 8 253 0.0001544 0.001213
593 REGULATION OF HORMONE LEVELS 11 478 0.0001557 0.001222
594 POSITIVE REGULATION OF MUSCLE CELL DIFFERENTIATION 5 84 0.0001573 0.001229
595 CELL MOTILITY 15 835 0.0001574 0.001229
596 LOCALIZATION OF CELL 15 835 0.0001574 0.001229
597 TRANSMEMBRANE RECEPTOR PROTEIN SERINE THREONINE KINASE SIGNALING PATHWAY 7 190 0.0001586 0.001236
598 SIGNAL TRANSDUCTION INVOLVED IN REGULATION OF GENE EXPRESSION 3 18 0.0001649 0.001283
599 REGULATION OF STRIATED MUSCLE CELL DIFFERENTIATION 5 85 0.0001663 0.001289
600 REGULATION OF CHROMOSOME SEGREGATION 5 85 0.0001663 0.001289
601 NEURON PROJECTION MORPHOGENESIS 10 402 0.0001678 0.001299
602 NEGATIVE REGULATION OF SEQUENCE SPECIFIC DNA BINDING TRANSCRIPTION FACTOR ACTIVITY 6 136 0.0001793 0.001386
603 CELL CYCLE CHECKPOINT 7 194 0.0001803 0.001391
604 ANTIGEN RECEPTOR MEDIATED SIGNALING PATHWAY 7 195 0.0001861 0.001431
605 POSITIVE REGULATION OF NEURON APOPTOTIC PROCESS 4 47 0.0001859 0.001431
606 REGULATION OF CARDIAC MUSCLE CELL DIFFERENTIATION 3 19 0.000195 0.001497
607 POSITIVE REGULATION OF PEPTIDYL SERINE PHOSPHORYLATION 5 88 0.0001957 0.001501
608 REGULATION OF CARDIAC MUSCLE TISSUE DEVELOPMENT 4 48 0.0002019 0.001543
609 POSITIVE REGULATION OF ACTIN FILAMENT BUNDLE ASSEMBLY 4 48 0.0002019 0.001543
610 EPITHELIAL CELL PROLIFERATION 5 89 0.0002064 0.001574
611 ESTABLISHMENT OR MAINTENANCE OF CELL POLARITY 6 141 0.0002182 0.001662
612 CELLULAR RESPONSE TO CALCIUM ION 4 49 0.0002188 0.001664
613 PLATELET ACTIVATION 6 142 0.0002267 0.001721
614 REGULATION OF DNA METABOLIC PROCESS 9 340 0.000227 0.001721
615 MULTICELLULAR ORGANISM REPRODUCTION 14 768 0.0002276 0.001722
616 TONGUE DEVELOPMENT 3 20 0.0002284 0.001725
617 REGULATION OF SKELETAL MUSCLE TISSUE DEVELOPMENT 4 50 0.0002368 0.001771
618 CELLULAR RESPONSE TO OXYGEN LEVELS 6 143 0.0002355 0.001771
619 FACE DEVELOPMENT 4 50 0.0002368 0.001771
620 ENDODERM FORMATION 4 50 0.0002368 0.001771
621 POSITIVE REGULATION OF MYELOID LEUKOCYTE DIFFERENTIATION 4 50 0.0002368 0.001771
622 NEGATIVE REGULATION OF INTRACELLULAR TRANSPORT 6 143 0.0002355 0.001771
623 NEGATIVE REGULATION OF CELL PROJECTION ORGANIZATION 6 144 0.0002445 0.001826
624 CELLULAR RESPONSE TO NITROGEN COMPOUND 11 505 0.0002501 0.001865
625 COVALENT CHROMATIN MODIFICATION 9 345 0.0002529 0.001883
626 BONE RESORPTION 3 21 0.0002653 0.001972
627 POSITIVE REGULATION OF REPRODUCTIVE PROCESS 4 52 0.0002757 0.002046
628 REGULATION OF TRANSCRIPTION FACTOR IMPORT INTO NUCLEUS 5 95 0.0002799 0.002074
629 MUSCLE ORGAN DEVELOPMENT 8 277 0.0002854 0.002111
630 POSITIVE REGULATION OF FIBROBLAST PROLIFERATION 4 53 0.0002969 0.002193
631 MODULATION OF TRANSCRIPTION IN OTHER ORGANISM INVOLVED IN SYMBIOTIC INTERACTION 3 22 0.0003058 0.002241
632 POSITIVE REGULATION OF MUSCLE HYPERTROPHY 3 22 0.0003058 0.002241
633 POSITIVE REGULATION OF CARDIAC MUSCLE HYPERTROPHY 3 22 0.0003058 0.002241
634 REGULATION OF STRIATED MUSCLE CELL APOPTOTIC PROCESS 3 22 0.0003058 0.002241
635 EMBRYONIC PLACENTA MORPHOGENESIS 3 22 0.0003058 0.002241
636 REGULATION OF PROTEIN MODIFICATION BY SMALL PROTEIN CONJUGATION OR REMOVAL 8 280 0.0003068 0.002245
637 GLAND MORPHOGENESIS 5 97 0.0003084 0.002253
638 CELLULAR RESPONSE TO CYTOKINE STIMULUS 12 606 0.0003114 0.002271
639 NEGATIVE REGULATION OF REPRODUCTIVE PROCESS 4 54 0.0003191 0.002316
640 REGULATION OF SECRETION 13 699 0.0003182 0.002316
641 VENTRICULAR SEPTUM DEVELOPMENT 4 54 0.0003191 0.002316
642 POSITIVE REGULATION OF PROTEASOMAL PROTEIN CATABOLIC PROCESS 5 98 0.0003234 0.002344
643 POSITIVE REGULATION OF NERVOUS SYSTEM DEVELOPMENT 10 437 0.000327 0.002359
644 INTRINSIC APOPTOTIC SIGNALING PATHWAY 6 152 0.0003271 0.002359
645 REGULATION OF CHROMATIN ORGANIZATION 6 152 0.0003271 0.002359
646 NEGATIVE REGULATION OF CELL CYCLE PROCESS 7 214 0.0003278 0.002361
647 MEMBRANE ORGANIZATION 15 899 0.0003476 0.0025
648 CELL CYCLE ARREST 6 154 0.0003508 0.002511
649 AMEBOIDAL TYPE CELL MIGRATION 6 154 0.0003508 0.002511
650 REGULATION OF OSTEOBLAST PROLIFERATION 3 23 0.0003502 0.002511
651 SMAD PROTEIN SIGNAL TRANSDUCTION 4 56 0.0003672 0.00262
652 POSITIVE REGULATION OF MUSCLE TISSUE DEVELOPMENT 4 56 0.0003672 0.00262
653 REGULATION OF EXTENT OF CELL GROWTH 5 101 0.0003718 0.002649
654 APOPTOTIC MITOCHONDRIAL CHANGES 4 57 0.0003931 0.002797
655 REGULATION OF HISTONE DEACETYLATION 3 24 0.0003984 0.002823
656 POSITIVE REGULATION OF DNA TEMPLATED TRANSCRIPTION INITIATION 3 24 0.0003984 0.002823
657 SYSTEM PROCESS 23 1785 0.0003986 0.002823
658 PROTEIN ACYLATION 6 159 0.0004159 0.002941
659 CEREBRAL CORTEX DEVELOPMENT 5 105 0.0004447 0.00313
660 REGULATION OF DNA REPLICATION 6 161 0.0004445 0.00313
661 ODONTOGENESIS 5 105 0.0004447 0.00313
662 LENS FIBER CELL DIFFERENTIATION 3 25 0.0004508 0.00314
663 SPINDLE CHECKPOINT 3 25 0.0004508 0.00314
664 FOREBRAIN REGIONALIZATION 3 25 0.0004508 0.00314
665 REGULATION OF FIBROBLAST GROWTH FACTOR RECEPTOR SIGNALING PATHWAY 3 25 0.0004508 0.00314
666 NEGATIVE REGULATION OF SMOOTHENED SIGNALING PATHWAY 3 25 0.0004508 0.00314
667 POSITIVE REGULATION OF PEPTIDYL THREONINE PHOSPHORYLATION 3 25 0.0004508 0.00314
668 VASCULOGENESIS 4 59 0.0004487 0.00314
669 CARDIAC VENTRICLE DEVELOPMENT 5 106 0.0004644 0.00323
670 NEGATIVE REGULATION OF CELL DIVISION 4 60 0.0004785 0.003318
671 CHONDROCYTE DIFFERENTIATION 4 60 0.0004785 0.003318
672 CELL SUBSTRATE ADHESION 6 164 0.0004902 0.003394
673 REGULATION OF CELL CYCLE ARREST 5 108 0.000506 0.003498
674 POSITIVE REGULATION OF SKELETAL MUSCLE TISSUE DEVELOPMENT 3 26 0.0005073 0.003502
675 REGULATION OF CELL CELL ADHESION 9 380 0.000511 0.003523
676 NEGATIVE REGULATION OF PROTEIN CATABOLIC PROCESS 5 109 0.0005278 0.003627
677 RESPONSE TO HYDROGEN PEROXIDE 5 109 0.0005278 0.003627
678 CELLULAR RESPONSE TO HORMONE STIMULUS 11 552 0.0005297 0.003635
679 REGULATION OF LEUKOCYTE DIFFERENTIATION 7 232 0.0005319 0.00364
680 POSITIVE REGULATION OF NEURON PROJECTION DEVELOPMENT 7 232 0.0005319 0.00364
681 POSITIVE REGULATION OF NUCLEAR DIVISION 4 62 0.0005423 0.003706
682 REGULATION OF ENDOTHELIAL CELL DIFFERENTIATION 3 27 0.0005682 0.003865
683 NEGATIVE REGULATION OF FIBROBLAST PROLIFERATION 3 27 0.0005682 0.003865
684 NEGATIVE REGULATION OF AXON GUIDANCE 3 27 0.0005682 0.003865
685 REGULATION OF CARTILAGE DEVELOPMENT 4 63 0.0005764 0.003915
686 HEMOSTASIS 8 311 0.000615 0.004171
687 PLACENTA BLOOD VESSEL DEVELOPMENT 3 28 0.0006336 0.00426
688 NEGATIVE REGULATION OF CHROMOSOME SEGREGATION 3 28 0.0006336 0.00426
689 CELL FATE COMMITMENT INVOLVED IN FORMATION OF PRIMARY GERM LAYER 3 28 0.0006336 0.00426
690 NEGATIVE REGULATION OF DENDRITE DEVELOPMENT 3 28 0.0006336 0.00426
691 REGULATION OF CELL SIZE 6 172 0.0006301 0.00426
692 METANEPHROS MORPHOGENESIS 3 28 0.0006336 0.00426
693 STRIATED MUSCLE CELL DIFFERENTIATION 6 173 0.0006495 0.004361
694 RESPONSE TO INTERLEUKIN 1 5 115 0.0006737 0.004517
695 REGULATION OF DEFENSE RESPONSE 13 759 0.0006907 0.004618
696 POSITIVE REGULATION OF CYTOSKELETON ORGANIZATION 6 175 0.0006898 0.004618
697 REGULATION OF MICROTUBULE BASED PROCESS 7 243 0.0006996 0.00467
698 FEMALE SEX DIFFERENTIATION 5 116 0.0007007 0.004671
699 REGULATION OF MEIOTIC NUCLEAR DIVISION 3 29 0.0007036 0.004677
700 NEUROBLAST PROLIFERATION 3 29 0.0007036 0.004677
701 POSITIVE REGULATION OF NEURON DEATH 4 67 0.0007281 0.004821
702 CELLULAR RESPONSE TO STARVATION 5 117 0.0007285 0.004821
703 CELLULAR RESPONSE TO DRUG 4 67 0.0007281 0.004821
704 POSITIVE REGULATION OF ENDOTHELIAL CELL PROLIFERATION 4 68 0.00077 0.005089
705 INTRINSIC APOPTOTIC SIGNALING PATHWAY IN RESPONSE TO DNA DAMAGE BY P53 CLASS MEDIATOR 3 30 0.0007784 0.005115
706 SMOOTH MUSCLE CELL DIFFERENTIATION 3 30 0.0007784 0.005115
707 POSITIVE REGULATION OF CYTOKINE PRODUCTION INVOLVED IN IMMUNE RESPONSE 3 30 0.0007784 0.005115
708 NEGATIVE REGULATION OF MUSCLE CELL APOPTOTIC PROCESS 3 30 0.0007784 0.005115
709 REGULATION OF CHEMOTAXIS 6 180 0.0007991 0.005244
710 NEGATIVE REGULATION OF OSSIFICATION 4 69 0.0008136 0.005324
711 POSITIVE REGULATION OF AXONOGENESIS 4 69 0.0008136 0.005324
712 RESPONSE TO KETONE 6 182 0.0008464 0.00553
713 REGULATION OF NEURON PROJECTION DEVELOPMENT 9 408 0.0008474 0.00553
714 INTERFERON GAMMA MEDIATED SIGNALING PATHWAY 4 70 0.0008589 0.005597
715 EMBRYONIC SKELETAL SYSTEM DEVELOPMENT 5 122 0.0008799 0.005718
716 CELLULAR RESPONSE TO INTERFERON GAMMA 5 122 0.0008799 0.005718
717 RESPONSE TO STEROID HORMONE 10 497 0.0008858 0.005748
718 CATABOLIC PROCESS 22 1773 0.0008999 0.005832
719 INTRINSIC APOPTOTIC SIGNALING PATHWAY IN RESPONSE TO DNA DAMAGE 4 71 0.000906 0.005855
720 CELL FATE SPECIFICATION 4 71 0.000906 0.005855
721 POSITIVE REGULATION OF MITOTIC CELL CYCLE 5 123 0.0009128 0.005891
722 REGULATION OF TRANSCRIPTION FROM RNA POLYMERASE II PROMOTER IN RESPONSE TO HYPOXIA 3 32 0.0009426 0.006074
723 REGULATION OF PEPTIDE TRANSPORT 7 256 0.000949 0.006108
724 ENDOTHELIAL CELL DIFFERENTIATION 4 72 0.0009548 0.006136
725 NEGATIVE REGULATION OF MAP KINASE ACTIVITY 4 73 0.001005 0.006435
726 G1 DNA DAMAGE CHECKPOINT 4 73 0.001005 0.006435
727 REGULATION OF NEURAL PRECURSOR CELL PROLIFERATION 4 73 0.001005 0.006435
728 REGULATION OF SYSTEM PROCESS 10 507 0.00103 0.006581
729 EMBRYONIC EYE MORPHOGENESIS 3 33 0.001032 0.006589
730 REGULATION OF DENDRITE MORPHOGENESIS 4 74 0.001058 0.006735
731 CELLULAR RESPONSE TO CARBOHYDRATE STIMULUS 4 74 0.001058 0.006735
732 NEGATIVE REGULATION OF NEURON DIFFERENTIATION 6 191 0.001086 0.006896
733 REGULATION OF HORMONE SECRETION 7 262 0.001086 0.006896
734 FOREBRAIN NEURON DEVELOPMENT 3 34 0.001127 0.007107
735 HOMEOSTATIC PROCESS 18 1337 0.001125 0.007107
736 ORGAN FORMATION 3 34 0.001127 0.007107
737 NEGATIVE REGULATION OF MITOTIC NUCLEAR DIVISION 3 34 0.001127 0.007107
738 NEURAL TUBE PATTERNING 3 34 0.001127 0.007107
739 PROTEIN ACETYLATION 5 129 0.00113 0.007114
740 REGULATION OF CALCIUM MEDIATED SIGNALING 4 76 0.001169 0.007349
741 DIENCEPHALON DEVELOPMENT 4 77 0.001227 0.007687
742 RESPONSE TO MINERALOCORTICOID 3 35 0.001227 0.007687
743 INNER EAR RECEPTOR CELL DEVELOPMENT 3 35 0.001227 0.007687
744 POSITIVE REGULATION OF PROTEIN MODIFICATION BY SMALL PROTEIN CONJUGATION OR REMOVAL 6 196 0.001241 0.007758
745 REGULATION OF RECEPTOR MEDIATED ENDOCYTOSIS 4 78 0.001288 0.008041
746 NEGATIVE REGULATION OF MUSCLE ORGAN DEVELOPMENT 3 36 0.001333 0.008293
747 NEGATIVE REGULATION OF MUSCLE TISSUE DEVELOPMENT 3 36 0.001333 0.008293
748 POSITIVE REGULATION OF CYCLIN DEPENDENT PROTEIN KINASE ACTIVITY 3 36 0.001333 0.008293
749 SMALL GTPASE MEDIATED SIGNAL TRANSDUCTION 8 352 0.001364 0.008475
750 NEGATIVE REGULATION OF RESPONSE TO EXTERNAL STIMULUS 7 274 0.001405 0.008715
751 REGULATION OF RESPONSE TO EXTERNAL STIMULUS 14 926 0.001429 0.008854
752 REGULATION OF RECEPTOR INTERNALIZATION 3 37 0.001444 0.008914
753 REGULATION OF PEPTIDYL THREONINE PHOSPHORYLATION 3 37 0.001444 0.008914
754 NEGATIVE REGULATION OF EPITHELIAL CELL DIFFERENTIATION 3 37 0.001444 0.008914
755 CIRCADIAN RHYTHM 5 137 0.001476 0.009096
756 METANEPHROS DEVELOPMENT 4 81 0.001481 0.009103
757 POSITIVE REGULATION OF MYELOID CELL DIFFERENTIATION 4 81 0.001481 0.009103
758 NEGATIVE REGULATION OF AXON EXTENSION 3 38 0.001561 0.009559
759 SUBSTRATE ADHESION DEPENDENT CELL SPREADING 3 38 0.001561 0.009559
760 REGULATION OF MULTICELLULAR ORGANISMAL METABOLIC PROCESS 3 38 0.001561 0.009559
761 CELL PART MORPHOGENESIS 11 633 0.001606 0.00982
NumGOOverlapSizeP ValueAdj. P Value
1 WNT PROTEIN BINDING 18 31 6.081e-33 5.649e-30
2 WNT ACTIVATED RECEPTOR ACTIVITY 16 22 8.322e-32 3.865e-29
3 BETA CATENIN BINDING 20 84 6.515e-27 1.766e-24
4 FRIZZLED BINDING 16 36 7.604e-27 1.766e-24
5 ENZYME BINDING 43 1737 1.991e-16 3.699e-14
6 PROTEIN SERINE THREONINE KINASE ACTIVITY 22 445 2.658e-14 4.115e-12
7 TRANSCRIPTION FACTOR BINDING 23 524 7.934e-14 1.053e-11
8 KINASE BINDING 23 606 1.62e-12 1.881e-10
9 SIGNAL TRANSDUCER ACTIVITY 37 1731 4.278e-12 3.974e-10
10 G PROTEIN COUPLED RECEPTOR BINDING 16 259 4.189e-12 3.974e-10
11 PROTEIN KINASE ACTIVITY 23 640 4.936e-12 4.169e-10
12 PROTEIN DOMAIN SPECIFIC BINDING 22 624 2.211e-11 1.711e-09
13 UBIQUITIN LIKE PROTEIN LIGASE BINDING 15 264 6.706e-11 4.76e-09
14 ARMADILLO REPEAT DOMAIN BINDING 6 13 7.173e-11 4.76e-09
15 RECEPTOR BINDING 32 1476 1.276e-10 7.9e-09
16 RECEPTOR AGONIST ACTIVITY 6 16 3.298e-10 1.802e-08
17 MOLECULAR FUNCTION REGULATOR 30 1353 3.279e-10 1.802e-08
18 SMAD BINDING 9 72 4.965e-10 2.563e-08
19 RNA POLYMERASE II TRANSCRIPTION FACTOR BINDING 10 104 7.289e-10 3.564e-08
20 KINASE ACTIVITY 23 842 1.123e-09 5.216e-08
21 PROTEIN PHOSPHATASE TYPE 2A REGULATOR ACTIVITY 6 21 2.18e-09 9.645e-08
22 I SMAD BINDING 5 11 3.347e-09 1.413e-07
23 REGULATORY REGION NUCLEIC ACID BINDING 22 818 3.622e-09 1.463e-07
24 RECEPTOR REGULATOR ACTIVITY 7 45 9.34e-09 3.615e-07
25 TRANSFERASE ACTIVITY TRANSFERRING PHOSPHORUS CONTAINING GROUPS 23 992 2.456e-08 9.128e-07
26 RECEPTOR ACTIVATOR ACTIVITY 6 32 3.449e-08 1.232e-06
27 RNA POLYMERASE II TRANSCRIPTION FACTOR ACTIVITY SEQUENCE SPECIFIC DNA BINDING 18 629 4.446e-08 1.53e-06
28 CORE PROMOTER PROXIMAL REGION DNA BINDING 14 371 5.627e-08 1.867e-06
29 TRANSCRIPTIONAL ACTIVATOR ACTIVITY RNA POLYMERASE II TRANSCRIPTION REGULATORY REGION SEQUENCE SPECIFIC BINDING 13 315 6.131e-08 1.964e-06
30 PROTEIN DIMERIZATION ACTIVITY 24 1149 8.346e-08 2.585e-06
31 R SMAD BINDING 5 23 2.3e-07 6.893e-06
32 RHO GTPASE BINDING 7 78 4.612e-07 1.339e-05
33 GAMMA CATENIN BINDING 4 12 6.077e-07 1.711e-05
34 PHOSPHATASE REGULATOR ACTIVITY 7 87 9.753e-07 2.665e-05
35 MAP KINASE ACTIVITY 4 14 1.218e-06 3.084e-05
36 ACTIVATING TRANSCRIPTION FACTOR BINDING 6 57 1.221e-06 3.084e-05
37 PDZ DOMAIN BINDING 7 90 1.228e-06 3.084e-05
38 PROTEIN SERINE THREONINE PHOSPHATASE ACTIVITY 6 64 2.437e-06 5.66e-05
39 RNA POLYMERASE II ACTIVATING TRANSCRIPTION FACTOR BINDING 5 36 2.42e-06 5.66e-05
40 CHROMATIN BINDING 13 435 2.379e-06 5.66e-05
41 NUCLEIC ACID BINDING TRANSCRIPTION FACTOR ACTIVITY 22 1199 2.732e-06 6.044e-05
42 TRANSCRIPTION FACTOR ACTIVITY PROTEIN BINDING 15 588 2.706e-06 6.044e-05
43 DOUBLE STRANDED DNA BINDING 17 764 3.532e-06 7.631e-05
44 SEQUENCE SPECIFIC DNA BINDING 20 1037 3.953e-06 8.346e-05
45 ENZYME REGULATOR ACTIVITY 19 959 4.84e-06 9.992e-05
46 TRANSCRIPTION FACTOR ACTIVITY RNA POLYMERASE II CORE PROMOTER PROXIMAL REGION SEQUENCE SPECIFIC BINDING 11 328 5.011e-06 0.0001012
47 TRANSCRIPTIONAL ACTIVATOR ACTIVITY RNA POLYMERASE II CORE PROMOTER PROXIMAL REGION SEQUENCE SPECIFIC BINDING 9 226 9.671e-06 0.0001912
48 RECEPTOR SIGNALING PROTEIN ACTIVITY 8 172 1.002e-05 0.0001939
49 IDENTICAL PROTEIN BINDING 21 1209 1.105e-05 0.0002052
50 ADENYL NUCLEOTIDE BINDING 24 1514 1.104e-05 0.0002052
51 TRANSCRIPTION COACTIVATOR ACTIVITY 10 296 1.29e-05 0.0002349
52 CALMODULIN BINDING 8 179 1.34e-05 0.0002394
53 RIBONUCLEOTIDE BINDING 27 1860 1.4e-05 0.0002454
54 CALMODULIN DEPENDENT PROTEIN KINASE ACTIVITY 4 28 2.332e-05 0.0004013
55 PROTEIN HETERODIMERIZATION ACTIVITY 12 468 2.731e-05 0.0004613
56 PROTEIN HOMODIMERIZATION ACTIVITY 15 722 3.09e-05 0.0005126
57 P53 BINDING 5 67 5.339e-05 0.0008701
58 PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR BINDING 3 15 9.32e-05 0.001475
59 MACROMOLECULAR COMPLEX BINDING 21 1399 9.369e-05 0.001475
60 PHOSPHOPROTEIN PHOSPHATASE ACTIVITY 7 178 0.0001058 0.001638
61 RECEPTOR SIGNALING PROTEIN SERINE THREONINE KINASE ACTIVITY 5 92 0.000241 0.003671
62 ENHANCER BINDING 5 93 0.0002535 0.003799
63 MITOGEN ACTIVATED PROTEIN KINASE BINDING 3 24 0.0003984 0.005875
64 PHOSPHORIC ESTER HYDROLASE ACTIVITY 9 368 0.0004054 0.005884
65 GTPASE BINDING 8 295 0.0004344 0.006209
66 HORMONE RECEPTOR BINDING 6 168 0.0005567 0.007719
67 TRANSCRIPTIONAL REPRESSOR ACTIVITY RNA POLYMERASE II TRANSCRIPTION REGULATORY REGION SEQUENCE SPECIFIC BINDING 6 168 0.0005567 0.007719
68 BHLH TRANSCRIPTION FACTOR BINDING 3 28 0.0006336 0.008656
NumGOOverlapSizeP ValueAdj. P Value
1 WNT SIGNALOSOME 10 11 4.918e-22 2.872e-19
2 BETA CATENIN DESTRUCTION COMPLEX 10 14 4.408e-20 1.287e-17
3 ENDOCYTIC VESICLE MEMBRANE 14 152 4.402e-13 8.57e-11
4 PHOSPHATASE COMPLEX 9 48 1.105e-11 1.613e-09
5 PROTEIN PHOSPHATASE TYPE 2A COMPLEX 7 20 1.808e-11 2.112e-09
6 ENDOCYTIC VESICLE 15 256 4.343e-11 4.227e-09
7 CATALYTIC COMPLEX 27 1038 9.192e-11 7.669e-09
8 NUCLEAR CHROMATIN 15 291 2.622e-10 1.914e-08
9 TRANSCRIPTION FACTOR COMPLEX 15 298 3.647e-10 2.367e-08
10 CHROMATIN 17 441 1.369e-09 7.993e-08
11 CHROMOSOME 23 880 2.61e-09 1.386e-07
12 LATERAL PLASMA MEMBRANE 7 50 2.005e-08 9.758e-07
13 VESICLE MEMBRANE 15 512 4.848e-07 2.178e-05
14 NUCLEAR CHROMOSOME 15 523 6.337e-07 2.522e-05
15 SYNAPSE 18 754 6.477e-07 2.522e-05
16 NUCLEAR TRANSCRIPTION FACTOR COMPLEX 8 127 1.045e-06 3.815e-05
17 INTRACELLULAR VESICLE 23 1259 1.679e-06 5.768e-05
18 SCF UBIQUITIN LIGASE COMPLEX 5 34 1.804e-06 5.852e-05
19 CYTOPLASMIC VESICLE PART 15 601 3.531e-06 0.0001085
20 TRANSFERASE COMPLEX 16 703 5.287e-06 0.0001544
21 EXTRACELLULAR MATRIX 12 426 1.078e-05 0.0002881
22 PROTEINACEOUS EXTRACELLULAR MATRIX 11 356 1.085e-05 0.0002881
23 PROTEIN KINASE COMPLEX 6 90 1.781e-05 0.0004521
24 GOLGI LUMEN 6 94 2.283e-05 0.0005556
25 RNA POLYMERASE II TRANSCRIPTION FACTOR COMPLEX 6 101 3.434e-05 0.0008021
26 CLATHRIN COATED ENDOCYTIC VESICLE 5 65 4.61e-05 0.0009971
27 CYTOSKELETAL PART 22 1436 4.586e-05 0.0009971
28 CELL SURFACE 15 757 5.3e-05 0.001105
29 MICROTUBULE CYTOSKELETON 18 1068 7.474e-05 0.001505
30 TRANSCRIPTIONAL REPRESSOR COMPLEX 5 74 8.61e-05 0.001622
31 LAMELLIPODIUM 7 172 8.537e-05 0.001622
32 EXCITATORY SYNAPSE 7 197 0.0001981 0.003573
33 CLATHRIN COATED ENDOCYTIC VESICLE MEMBRANE 4 48 0.0002019 0.003573
34 CYTOSKELETON 25 1967 0.0002626 0.00451
35 SYNAPSE PART 12 610 0.0003304 0.005514
36 CLATHRIN COATED VESICLE 6 157 0.0003888 0.005831
37 NUCLEAR EUCHROMATIN 3 24 0.0003984 0.005831
38 NUCLEOPLASM PART 13 708 0.0003595 0.005831
39 CYTOPLASMIC MICROTUBULE 4 57 0.0003931 0.005831
40 MICROTUBULE ORGANIZING CENTER 12 623 0.0003994 0.005831
41 COATED VESICLE 7 234 0.0005597 0.007972
42 TRANSFERASE COMPLEX TRANSFERRING PHOSPHORUS CONTAINING GROUPS 7 237 0.0006036 0.008393
43 EARLY ENDOSOME MEMBRANE 5 113 0.0006221 0.008449
44 CHROMOSOME CENTROMERIC REGION 6 174 0.0006694 0.008885
45 CENTROSOME 10 487 0.0007588 0.009848

Over-represented Pathway

NumPathwayPathviewOverlapSizeP ValueAdj. P Value
1 hsa04310_Wnt_signaling_pathway 121 151 1.76e-288 3.168e-286
2 hsa04390_Hippo_signaling_pathway 46 154 1.389e-67 1.25e-65
3 hsa04916_Melanogenesis 41 101 1.434e-66 8.602e-65
4 hsa04114_Oocyte_meiosis 23 114 4.909e-29 2.209e-27
5 hsa04340_Hedgehog_signaling_pathway 17 56 4.881e-25 1.757e-23
6 hsa04720_Long.term_potentiation 17 70 3.662e-23 1.099e-21
7 hsa04520_Adherens_junction 17 73 8.096e-23 2.082e-21
8 hsa04662_B_cell_receptor_signaling_pathway 15 75 3.661e-19 8.238e-18
9 hsa04010_MAPK_signaling_pathway 22 268 6.222e-19 1.244e-17
10 hsa04370_VEGF_signaling_pathway 14 76 2.038e-17 3.668e-16
11 hsa04912_GnRH_signaling_pathway 15 101 4.196e-17 6.866e-16
12 hsa04350_TGF.beta_signaling_pathway 14 85 1.077e-16 1.615e-15
13 hsa04360_Axon_guidance 15 130 2.063e-15 2.856e-14
14 hsa04110_Cell_cycle 14 128 3.972e-14 5.107e-13
15 hsa04510_Focal_adhesion 16 200 7.787e-14 9.345e-13
16 hsa04650_Natural_killer_cell_mediated_cytotoxicity 14 136 9.326e-14 1.012e-12
17 hsa04660_T_cell_receptor_signaling_pathway 13 108 9.558e-14 1.012e-12
18 hsa04012_ErbB_signaling_pathway 12 87 1.668e-13 1.668e-12
19 hsa04020_Calcium_signaling_pathway 15 177 2.101e-13 1.99e-12
20 hsa04971_Gastric_acid_secretion 11 74 7.584e-13 6.825e-12
21 hsa04722_Neurotrophin_signaling_pathway 11 127 3.086e-10 2.645e-09
22 hsa04380_Osteoclast_differentiation 11 128 3.359e-10 2.748e-09
23 hsa04151_PI3K_AKT_signaling_pathway 15 351 3.439e-09 2.692e-08
24 hsa04710_Circadian_rhythm_._mammal 6 23 4.016e-09 3.012e-08
25 hsa04062_Chemokine_signaling_pathway 11 189 2.075e-08 1.494e-07
26 hsa04664_Fc_epsilon_RI_signaling_pathway 8 79 2.59e-08 1.793e-07
27 hsa04270_Vascular_smooth_muscle_contraction 9 116 3.561e-08 2.374e-07
28 hsa04210_Apoptosis 8 89 6.667e-08 4.286e-07
29 hsa04730_Long.term_depression 7 70 2.178e-07 1.352e-06
30 hsa04330_Notch_signaling_pathway 6 47 3.795e-07 2.277e-06
31 hsa03015_mRNA_surveillance_pathway 7 83 7.069e-07 4.105e-06
32 hsa04970_Salivary_secretion 7 89 1.139e-06 6.405e-06
33 hsa04540_Gap_junction 7 90 1.228e-06 6.701e-06
34 hsa04530_Tight_junction 8 133 1.483e-06 7.849e-06
35 hsa04014_Ras_signaling_pathway 10 236 1.743e-06 8.964e-06
36 hsa04670_Leukocyte_transendothelial_migration 7 117 7.128e-06 3.564e-05
37 hsa04914_Progesterone.mediated_oocyte_maturation 6 87 1.466e-05 7.13e-05
38 hsa04910_Insulin_signaling_pathway 7 138 2.098e-05 9.936e-05
39 hsa04620_Toll.like_receptor_signaling_pathway 6 102 3.631e-05 0.0001676
40 hsa04115_p53_signaling_pathway 5 69 6.153e-05 0.0002769
41 hsa04120_Ubiquitin_mediated_proteolysis 6 139 0.0002019 0.0008865
42 hsa04810_Regulation_of_actin_cytoskeleton 7 214 0.0003278 0.001405
43 hsa04630_Jak.STAT_signaling_pathway 6 155 0.0003631 0.00152
44 hsa04972_Pancreatic_secretion 5 101 0.0003718 0.001521
45 hsa04621_NOD.like_receptor_signaling_pathway 4 59 0.0004487 0.001795
46 hsa04141_Protein_processing_in_endoplasmic_reticulum 6 168 0.0005567 0.002178
47 hsa04622_RIG.I.like_receptor_signaling_pathway 4 71 0.000906 0.00347
48 hsa04070_Phosphatidylinositol_signaling_system 4 78 0.001288 0.004828
49 hsa04962_Vasopressin.regulated_water_reabsorption 3 44 0.002387 0.00877
50 hsa04666_Fc_gamma_R.mediated_phagocytosis 4 95 0.002656 0.009562
51 hsa04742_Taste_transduction 3 52 0.003847 0.01358
52 hsa04920_Adipocytokine_signaling_pathway 3 68 0.008134 0.02816
53 hsa04976_Bile_secretion 3 71 0.009156 0.0311
54 hsa04740_Olfactory_transduction 7 388 0.009365 0.03122
55 hsa04960_Aldosterone.regulated_sodium_reabsorption 2 42 0.0267 0.08738
56 hsa00562_Inositol_phosphate_metabolism 2 57 0.04669 0.1501
57 hsa03008_Ribosome_biogenesis_in_eukaryotes 2 81 0.08642 0.2729
58 hsa04144_Endocytosis 2 203 0.3482 1

lncRNA-mediated sponge

(Download full result)

Num lncRNA miRNAs           miRNAs count     Gene Sponge regulatory network lncRNA log2FC lncRNA pvalue Gene log2FC Gene pvalue lncRNA-gene Pearson correlation
1 LDLRAD4-AS1 hsa-miR-106b-5p;hsa-miR-132-3p;hsa-miR-17-3p;hsa-miR-17-5p;hsa-miR-20a-5p;hsa-miR-21-5p;hsa-miR-301a-3p;hsa-miR-3127-5p;hsa-miR-454-3p;hsa-miR-589-3p 10 FZD4 Sponge network -3.366 0 -0.346 0.01097 0.404
2 AC005550.3 hsa-miR-181a-5p;hsa-miR-181b-5p;hsa-miR-183-5p;hsa-miR-19a-3p;hsa-miR-19b-3p;hsa-miR-21-5p;hsa-miR-301a-3p;hsa-miR-362-3p;hsa-miR-92a-3p;hsa-miR-92b-3p 10 DAAM1 Sponge network -2.571 0.00132 -0.82 3.0E-5 0.394
3

RP11-166D19.1

 hsa-miR-106b-5p;hsa-miR-17-3p;hsa-miR-17-5p;hsa-miR-185-5p;hsa-miR-20a-5p;hsa-miR-21-5p;hsa-miR-301a-3p;hsa-miR-32-3p;hsa-miR-32-5p;hsa-miR-324-3p;hsa-miR-330-5p;hsa-miR-361-5p;hsa-miR-484;hsa-miR-589-3p;hsa-miR-590-5p;hsa-miR-629-3p;hsa-miR-92a-3p;hsa-miR-940 18 FZD4 Sponge network -0.244 0.28835 -0.346 0.01097 0.384
4

MAGI2-AS3

 hsa-miR-106a-5p;hsa-miR-106b-5p;hsa-miR-1266-5p;hsa-miR-15b-5p;hsa-miR-17-5p;hsa-miR-193a-3p;hsa-miR-19a-3p;hsa-miR-19b-1-5p;hsa-miR-19b-3p;hsa-miR-20a-5p;hsa-miR-425-5p;hsa-miR-589-3p;hsa-miR-616-5p;hsa-miR-9-5p;hsa-miR-92a-3p;hsa-miR-93-5p 16 CCND1 Sponge network -1.801 0 -0.902 1.0E-5 0.359
5 RP11-12A2.3 hsa-let-7d-5p;hsa-miR-106b-5p;hsa-miR-132-3p;hsa-miR-17-3p;hsa-miR-17-5p;hsa-miR-185-5p;hsa-miR-20a-5p;hsa-miR-21-5p;hsa-miR-301a-3p;hsa-miR-330-5p;hsa-miR-92a-3p 11 FZD4 Sponge network -4.779 0 -0.346 0.01097 0.342
6 RP11-7F17.3 hsa-let-7d-5p;hsa-miR-106b-5p;hsa-miR-132-3p;hsa-miR-17-3p;hsa-miR-17-5p;hsa-miR-20a-5p;hsa-miR-21-5p;hsa-miR-301a-3p;hsa-miR-3127-5p;hsa-miR-324-3p;hsa-miR-330-5p;hsa-miR-940 12 FZD4 Sponge network -0.873 0.00204 -0.346 0.01097 0.341
7 RP11-480I12.7 hsa-miR-142-5p;hsa-miR-146a-5p;hsa-miR-150-5p;hsa-miR-218-5p;hsa-miR-22-5p;hsa-miR-2355-3p;hsa-miR-24-2-5p;hsa-miR-330-3p;hsa-miR-381-3p;hsa-miR-495-3p 10 PRKCA Sponge network 2.03 0 0.663 0 0.332
8 MIR497HG hsa-miR-106b-5p;hsa-miR-17-3p;hsa-miR-17-5p;hsa-miR-185-5p;hsa-miR-20a-5p;hsa-miR-21-5p;hsa-miR-301a-3p;hsa-miR-32-3p;hsa-miR-324-3p;hsa-miR-589-3p;hsa-miR-940 11 FZD4 Sponge network -0.886 0.00689 -0.346 0.01097 0.313
9 TOB1-AS1 hsa-miR-142-5p;hsa-miR-146a-5p;hsa-miR-150-5p;hsa-miR-181a-5p;hsa-miR-181b-5p;hsa-miR-181c-5p;hsa-miR-218-5p;hsa-miR-2355-3p;hsa-miR-330-3p;hsa-miR-450b-5p 10 PRKCA Sponge network 0.811 0 0.663 0 0.308
10 LINC00261 hsa-miR-106b-5p;hsa-miR-132-3p;hsa-miR-21-5p;hsa-miR-301a-3p;hsa-miR-3127-5p;hsa-miR-324-3p;hsa-miR-330-5p;hsa-miR-454-3p;hsa-miR-589-3p;hsa-miR-629-3p;hsa-miR-940 11 FZD4 Sponge network -1.194 0 -0.346 0.01097 0.3
11 CASC2 hsa-miR-107;hsa-miR-148b-3p;hsa-miR-17-3p;hsa-miR-192-3p;hsa-miR-193a-3p;hsa-miR-194-3p;hsa-miR-194-5p;hsa-miR-21-5p;hsa-miR-362-5p;hsa-miR-548j-5p;hsa-miR-885-5p 11 NFAT5 Sponge network -0.596 0.00187 -0.326 0.00164 0.281
12 RP11-539I5.1 hsa-miR-107;hsa-miR-130b-3p;hsa-miR-17-5p;hsa-miR-194-5p;hsa-miR-19a-3p;hsa-miR-19b-3p;hsa-miR-20a-5p;hsa-miR-30b-3p;hsa-miR-30d-5p;hsa-miR-30e-5p;hsa-miR-32-3p 11 FZD3 Sponge network -1.111 0.02467 -0.432 0.07605 0.259
13 SMIM2-AS1 hsa-let-7d-5p;hsa-miR-106b-5p;hsa-miR-132-3p;hsa-miR-17-5p;hsa-miR-20a-5p;hsa-miR-21-5p;hsa-miR-301a-3p;hsa-miR-3127-5p;hsa-miR-330-5p;hsa-miR-589-3p;hsa-miR-629-3p;hsa-miR-940;hsa-miR-98-5p 13 FZD4 Sponge network -0.66 0.00587 -0.346 0.01097 0.253
14

RP11-166D19.1

 hsa-miR-106a-5p;hsa-miR-106b-5p;hsa-miR-1266-5p;hsa-miR-15b-5p;hsa-miR-16-5p;hsa-miR-17-5p;hsa-miR-186-5p;hsa-miR-193a-3p;hsa-miR-19a-3p;hsa-miR-19b-1-5p;hsa-miR-19b-3p;hsa-miR-20a-5p;hsa-miR-425-5p;hsa-miR-589-3p;hsa-miR-616-5p;hsa-miR-92a-3p;hsa-miR-942-5p 17 CCND1 Sponge network -0.244 0.28835 -0.902 1.0E-5 0.253

Quest ID: bc977c43b96e3467b06c53373b88ab5f